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Cardiovascular disease leads in morbidity and mortality in Western societies with
no known cure. NADPH oxidase (Nox) contributes to atherosclerosis through the
indirect activation of macrophages leading to the internalization of oxidized low density
lipoproteins (oxLDL). Chronic inflammation in activated macrophages contributes to
atherosclerosis. Because macrophages are positioned at the cross-roads of lipid
metabolism in vessel walls, they are important in the cellular pathology of
atherosclerosis. Components of the endocannabinoid (eCB) system are vital to
atherosclerotic development, since the eCB system has been found to play an important
role in the amelioration of atherosclerosis. The eCB system has several components,
including the G-protein-coupled cannabinoid receptors (CB1 and CB2); their endogenous
ligands, 2-arachidonoylglycerol (2-AG) and anandamide (AEA); and biosynthetic
enzymes that produce and degrading these compounds. CB2 signaling has been shown to
upregulate immunoprotective and anti-oxidative pathways, whereas CB1 signaling has
opposite effects. We hypothesized a mechanistic link between scavenger receptor
activation and Nox activity, which leads to enhanced 2-AG biosynthesis via a signaling
pathway that activates diacylglycerol lipase beta (DAGLB). Activation of CB2-mediated

signaling by enhanced “eCB tone” can potentially reduce oxidative stress in
macrophages. The released 2-AG is subsequently catabolized hydrolytic enzymes,
leading to enhanced 2-AGbiosynthesis via activated DAGLB. We first proved that
macrophage treated with oxLDL can activate Nox and increase reactive oxygen species
production. We used human and mouse macrophages to demonstrate cause and effect.
Secondly, we demonstrated that increased levels of superoxide causes enhanced 2-AG
biosynthesis within the macrophage, and that upregulation in eCB production is an
adaptive response to oxidative stress. Finally, we identified and quantified the serine
hydrolases found in smooth muscle cells (SMCs) using an activity-based protein profiling
(ABPP)-MudPIT approach that our laboratory has previously done using human
macrophages. Additionally, the catabolism of 2-AG by primary SMCs was explored to
demonstrate SMCs can hydrolyze 2-AG to its metabolites arachidonic acid and glycerol
by the known hydrolytic enzymes. We demonstrated that enhancing endocannabinoid
tone within the vessel wall is a valuable strategy to reduce the occurrence of
inflammation that leads to atherosclerosis.
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CHAPTER I
INTRODUCTION TO DISSERTATION
1.1

Introduction
The incidence of cardiovascular disease (CVD) in industrialized countries has

remained constant over several years, yet it remains the number one cause of death.
Furthermore, though there is a myriad of information and ongoing research pertaining to
controlling the underlying factors of CVD, including hypertension, hyperlipidemia, and
obesity, among others. CVD is becoming more prevalent in developing countries.
Atherosclerosis, which is the major cause of CVD, is a chronic inflammatory disease that
involves lipid dysregulation as its major hallmark. This results in the occurrence of
plaque formation and the hardening of the vessel wall. There are several homeostatic
mechanisms that can act to slow the onset of atherosclerosis, including the upregulation
of the endocannabinoid system, enhanced reverse cholesterol transport, and the
downregulation of genes that encode pro-inflammatory cytokines. Pharmaceutical
therapy has made important advances over the past several decades; however, because
CVD remains the number one killer in the United States, it is important to identify targets
for new therapeutic agents that will decrease the tendency of cardiovascular disease
development.

1

1.2

Treatment strategies in cardiovascular disease
Each year CVD remains among the top chronic illnesses and the leading health

problem in the U.S. According to the American Heart Foundation, cancer deaths pale in
comparison to CVD in terms of the number of lives claimed each year (Lori Mosca et al.
2011). Although CVD is an equal opportunity disease, more lives of women than men
are claimed each year, due to the different warning signs, but both men and women are
treated the same in regards to pharmaceutical therapies (Lori Mosca et al. 2011; Smith et
al. 2011; Gouni-Berthold and Berthold 2015).
Currently, treatment strategies for CVD are aimed at relieving the symptoms,
reducing risk factors, and increasing blood flow within the heart. Genetic and
environmental factors play a significant role in the onset of CVD. The growing trend of a
sedentary lifestyle and increased high-fat diet contributes to early onset of CVD.
Although genes are obviously hereditary, poor diet and exercise habits can also be passed
down from parent to progeny, thus perpetuating a cycle of decreased fitness and declining
health. As modern society has become more fast-paced, many people are choosing fast
food and processed foods that are high in sodium and saturated fats rather than a heart
healthy diet. It is suggested that behavioral changes alone may be a way to decrease the
onset of CVD, thus the National Heart Lung and Blood Institute (NHLBI) has proposed
dietary approaches to reduce hypertension, which is often the “silent killer” in patients
with CVD. However, exogenous toxicants, such as cigarette smoke, can also
significantly increase the risk for CVD. Quitting smoking coupled to a healthy diet and
exercise are important lifestyle modifications to control heart disease. Cigarette smoke
has an arsenal of toxic chemicals that can damage the vascular wall via multiple
2

pathological pathways (Csordas and Bernhard 2013; Ross et al. 2014). Furthermore,
several components in cigarette smoke can increase reactive oxygen species levels, such
as superoxide, which leads to increased oxidative stress. When combined with other
factors, such as an unhealthy diet, limited exercise, and obesity, smoking leads to an
enhanced prevalence for peripheral arterial disease. Taken together, limiting behaviors
that contribute to oxidative stress can help decrease the risk of myocardial infarctions and
sudden death.
Anti-hypertensives and statins are widely used pharmaceuticals to control CVD
by decreasing the risk factors of hypertension and hyperlipidemia, respectively. Blood
pressure is controlled physiologically by the renin-angiotensin system (RAS). RAS is
comprised of angiotensin (Ang) II acting on either type I or type II receptors (AT1R or
AT2R, respectively), which are members of the G-protein coupled receptor superfamily
(Arumugam S 2015). Reactive oxygen species cause a number of dysfunctions within
the vascular wall, thus AT1R blockers are some of the leading therapeutics used to
prevent myocardial infarction, stroke, renal disease, and heart failure. For example,
sartan drugs, such as Losartan, is a combination of two pro-drugs that are activated in the
liver. One of the drugs acts to block the AT1R, while the other decreases oxidative stress
(Arumugam S 2015). Sartan drugs have been shown to play a role in reducing cytokine
production, apoptosis, and diminish inflammatory phenotypes in macrophages
(Yamamoto et al. 2015). Furthermore, in a study using a rat model of vascular
calcification, Li et al (2015) revealed that Losartan has the ability to suppress key factors
involved in vascular calcification and smooth muscle cell apoptosis. Although there are
clear beneficial effects of medicinal therapy to treat hypertension (Chida et al. 2015),
3

more studies are needed to identify the overall biomarkers of cardiac function and lipid
parameters. On the other hand, studies have shown that statins have the ability to reduce
medial thickness and perivascular fibrosis in the aorta without affecting the inducible and
endothelial nitric oxide synthase (Crespo and Quidgley 2015). There are significant
clinical benefits with the use of both sartans and statins, however, not without
consequences including statin induced myopathy, liver damage, increased blood sugar,
and neurological side effects (Fernandez et al. 2011; Phan et al. 2012; Clinic 2015).
Statins, phospholipase A2 inhibitor, lipoprotein-associated phospholipase A2
inhibitor, RAS inhibitors, and Ang II receptor blockers are anti-inflammatory agents that
have been linked to reduced progression of atherosclerosis and decreased vascular
inflammatory markers (Husain et al. 2015). However, despite advancement in drug
therapy the onset of atherosclerosis disappointingly remains the leading cause of
mortality, morbidity and decreased quality of life. Being that both endogenous and
exogenous chemicals participate in the onset of CVD, current research is directed toward
alternative strategies to ameliorate the occurrence of atherosclerosis.
1.3

Research Overview
Oxidative stress contributes to development of atherosclerosis, which is the

leading cause of morbidity and mortality in adults. Atherosclerosis is a chronic
inflammatory disease that is associated with obesity, diabetes, and an overactive immune
response. In addition, the endocannabinoid system (ECS) has also been shown to be
involved in atherosclerosis. The ECS is composed of a variety of components, including
the G-protein coupled cannabinoid receptors (CB1 and CB2); endogenous
endocannabinoid ligands, 2-arachidonoylglycerol (2-AG) and anandamide (AEA);
4

hydrolytic enzymes that degrade these ligands; and cyclooxygenase-2 (COX2), which
yields proinflammatory prostaglandin glyceryl esters (PG-Gs) following the oxygenation
of 2-AG. CB2 activation and signaling has been shown to initiate immuno-protective
pathways through the modulation of anti-inflammatory mediators; whereas, CB1
signaling has been linked to pro-inflammatory reactions. Thus, the ECS may contribute
to disease pathogenesis and needs to be studied in more depth within the context of
atherosclerosis. The links between the ECS, oxidative stress, and atherosclerosis lead us
to speculate that modulation of the ECS can reduce the extent of atherosclerosis. Limited
knowledge currently exists concerning the scavenger receptors (SR), such as CD36, and
the subsequent activation of NADPH oxidase and generation of superoxide in
macrophages following engagement with oxidized low density lipoproteins (oxLDL)
(Figure 1.1). We hypothesize that stimulated NADPH oxidase activity and oxidative
stress leads to enhanced biosynthesis of 2-AG via a signaling pathway that activates
diacylglycerol lipase beta (DAGLβ). Additionally, enhanced “endocannabinoid
tone” can potentially reduce the oxidative stress in macrophages. We will test this
hypothesis with the following specific aims:
1.3.1

Specific Aim 1
Determine whether NADPH oxidase activity is increased following activation of

SR by oxLDL. Our working hypothesis was that ligation of SR by oxLDL will activate
NADPH oxidase and increase ROS production. This was explored using HL-60
macrophages-like cells because they express abundant levels of Nox2. Nox2 is the
catalytic subunit of NADPH oxidase in macrophages.
5

1.3.1.1

Overview of Aim 1
There is evidence that apocynin, an NADPH oxidase inhibitor, is a promising

therapeutic agent for the treatment of inflammatory diseases. In addition, CD36 is a
scavenger receptor expressed on macrophages that interacts with oxidized phospholipids
present in oxLDL particles (Park et al 2009). Because NADPH oxidase activation
contributes to the upregulation of CD36 (Boyer et al., 2007), it was the objective of this
aim to determine if a converse response on NADPH oxidase occurs following ligation of
SR by oxLDL. We tested the working hypothesis that oxLDLs activates SR-evoked
signaling and that NADPH oxidase activity could be consequently augmented in
VAS2870 and apocynin-treated macrophages, but not control macrophages. The
rationale for this aim was to determine the change in activity of NADPH oxidase in
macrophages during conditions of increased oxLDL exposure, which arises during
atherogenesis.
1.3.1.2

Significance of Aim 1
During atherosclerosis, macrophages become foam cells via the uptake of excess

fatty acids and cholesterol. The mechanism of reverse cholesterol transport (RCT) in the
macrophage is a means of reducing cholesterol accumulation and ROS within the cell.
NADPH oxidase plays a vital role in the production of ROS. The mechanism of NADPH
oxidase activation (Nox2 isoform in macrophages) involves phosphorylation of a
cytosolic p47phox subunit and its subsequent translocation to membranes where Nox2 is
found. Inhibition of NADPH oxidase through pharmacological or genetic manipulation
has yet to be explored as a means of reducing oxLDL uptake into the macrophage.
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1.3.2

Specific Aim 2
Determine whether exposing macrophages in vitro to ROS leads to activation of

DAGLβ and increased biosynthesis of 2-AG, thereby enhancing macrophage
"endocannabinoid tone”. Our working hypothesis is that a correlation exists between
increased levels of superoxide and enhanced 2-AG biosynthesis rate within the
macrophage; therefore, elevated 2-AG levels may be an adaptive response to oxidative
stress.
1.3.2.1

Overview of Aim 2
Oxidative stress is enhanced during atherogenesis; thus, cells in the vessel wall

such as macrophages may become compromised. The objective of this aim was to
determine whether macrophages exposed to superoxide have an increased rate of 2-AG
biosynthesis. The source of superoxide will be either in situ xanthine/xanthine oxidase
generated extracellular superoxide or intracellularly formed superoxide generated by
NADPH oxidase. We tested the working hypothesis that enhanced 2-AG levels may be
an adaptive response to oxidative stress that results in a positive correlation between
increased levels of superoxide and enhanced 2-AG biosynthesis within the macrophage.
The approach included gene and protein expression analyses of diacylglycerol lipase
(DAGL); LC-MS/MS analysis of 2-AG levels in macrophages; and serine hydrolase
activity profiling of key enzymes. The rationale was to elucidate the role of DAGL in
the biosynthesis of 2-AG during oxidative stress. The primary outcome of this aim was
the characterization of the “endocannabinoid tone” upon exposure of macrophages to
oxidative stress (e.g., superoxide). A second outcome was an assessment of changes in
inflammation in the macrophage in the presence of increased 2-AG concentration. This
7

aim revealed the role of DAGL in 2-AG production as a consequence of superoxide
exposure.
1.3.2.2

Significance of Aim 2
The synthesis and release of 2-AG is stimulus-dependent and relies on the

concerted action of phospholipase C-β (PLC-β) and DAGL (Gregg et al., 2012), thus
elucidating whether superoxide can affect DAGL activation and alter the ECS is both
novel and significant.
1.3.3

Specific Aim 3
Compare the serine hydrolase profiles in human smooth muscle cells (SMCs) and

determine the extent of 2-AG metabolism by SMCs. Our working hypothesis was that
while macrophages are elite producers of bioactive lipid mediators such as 2-AG, other
cell types in the vessel wall in addition to macrophages may have roles in the catabolism
of this endocannabinoid. Therefore, we identified the 2-AG hydrolytic enzymes and their
activities in cultured human SMCs.
1.3.3.1

Overview of Aim 3
Little is understood regarding the metabolism of 2-AG by ECs and SMCs in the

vessel wall. Therefore, we profiled the serine hydrolases found in cultured human SMCs
using the ABPP-MUDPIT approach that we recently used with human THP1
monocytes/macrophages (Wang et al., 2013). We prepared cell proteomes of cultured
primary human SMCs and treated them with the activity-based probe fluorophosphonate
(FP)-biotin. We labeled the serine hydrolases with FP-biotin to identify and semiquantify them following their enrichment on streptavidin beads and on-bead trypsin
8

digestion followed by LC-MS/MS analysis. Moreover, the extent of metabolism of
exogenously added 2-AG to the cultured SMCs was also determined, as our laboratory
has done previously using monocytes/macrophages (Xie et al. 2010; Wang et al. 2013).
Both the hydrolytic and oxidative pathways of 2-AG catabolism was examined in these
cells.
1.3.3.2

Significance of Aim 3
There is speculation that SMCs produce danger-associated signals that are similar

to those of macrophages. Thus they could potentially have the biochemistry to produce
the enzymes necessary to lead to the phenotypic changes that lead to SMC foam cell
formation. Additionally, serine hydrolase activity has been shown to play a role in the
activation of the endocannabinoid receptors due to sustained availability of the ligand 2AG (i.e., lower activity of 2-AG hydrolytic enzymes leads to higher concentrations of 2AG). These data could provide evidence for the necessity to explore the SMC further as
a means of combating atherosclerosis.

9

Figure 1.1

Pathways to be investigated in macrophages.

Because DAGLβ catalyzes the biosynthesis of 2-AG, we explored the mechanistic links
between scavenger receptor (such as CD36) activation by oxLDL, NADPH oxidase
activation, and enhanced 2-AG biosynthesis via DAGLβ activation. Furthermore, we
examined the metabolism of the released extracellular 2-AG by cultured primary human
smooth muscle cells.
DAGLβ, diacylglycerol lipase beta; oxLDL, oxidized low-density lipoprotein; PPT1,
palmitoyl protein thioesterase 1; CES1, carboxylesterase 1.
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CHAPTER II
OXYRADICAL STRESS, ENDOCANNABINOIDS, AND ATHEROSCLEROSIS
2.1

Introduction
Atherosclerosis is the major underlying pathology that causes cardiovascular

disease (CVD). Despite considerable investment in the development of new therapies,
atherosclerosis remains the leading cause of morbidity and mortality in industrialized
societies. At its heart, atherosclerosis is a chronic inflammatory disease caused by
inflammatory cascades, dysregulated lipid metabolism, and oxidative stress (Ross et al.
2014). Exogenous and endogenous small molecules – and the enzymes that produce or
degrade these molecules – have important roles in these processes. This review will
focus on reactive oxygen species (ROS), their important roles in intracellular signaling
pathways, and the impact that dysregulated ROS signaling has in pathophysiological
processes, such as atherogenesis. In addition, though atherosclerosis is a multifactorial
disease involving endothelial cell dysfunction, hypertension, hyperlipidemia,
inflammation, and imbalances in ROS formation and degradation, there is also emerging
knowledge that the endocannabinoid system has an important role in atherogenesis.
Thus, the role of the endocannabinoids will be discussed in the context of inflammation
and atherosclerosis.
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2.2

Macrophage cholesterol metabolism
Reverse cholesterol transport (RCT) is an endogenous pathway that has the

propensity to maintain homeostasis and reduce inflammation in the vessel wall.
Cholesterol is an indispensable molecule for proper functioning and organization of the
plasma membrane; however, when low density lipoproteins (LDL) substantially
outnumber high density lipoproteins (HDL) it becomes necessary for de novo synthesis
of HDL via the RCT system. RCT system is induced to restore the balance of LDL and
HDL. Ordinarily, free (unesterified) cholesterol is trafficked along endocytic and
secretory pathways that involve ATP-binding cassette (ABC) A1 and ABCG1 that efflux
lipids and free cholesterol to apolipoprotein A-1 (ApoA-1) for HDL biogenesis (Phillips
2014). It is when LDLs become modified or oxidized that the macrophage has a limited
potential to metabolize the lipids into an aqueous phase for facilitated diffusion to
translocate the lipids across the cell membrane (Wustner and Solanko 2015). ApoA-1 is
an acceptor for free cholesterol thereby forming a mature HDL particle (Brown et al.
1979) followed by the conversion of cholesterol to cholesteryl esters, which can be
transferred from HDL to LDL by cholesteryl ester transfer protein (Westerterp et al.
2014). The LDL particles in the circulation are then taken up by LDL receptors on liver
cells (hepatocytes). The cholesteryl esters are de-esterified to free cholesterol in the
hepatocytes and delivered to the bile for disposal after being converted to bile acids.
Atherosclerosis is caused in part by oxidized (ox)LDL being phagocytosed by
macrophages, leading to foam cell formation. Previous reports have indicated that oxLDL
interacts with the CD36 receptor (Park et al. 2009) evoking a signaling pathway that
activates the NADPH oxidase (Nox) complex (Miller et al. 2011). Park et al (2009)
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demonstrated that oxLDL induces actin polymerization in the presence of CD36,
resulting in the sustained activation of focal adhesion kinase (FAK) and inactivating the
Src homology-2 containing phosphotyrosine phosphatase (SHP-2) due to Nox mediated
ROS generation. Because SHP-2 is a phosphatase that diminishes signaling, its
inactivation should enhance signaling. With oxLDL being an endogenous Nox activator,
it is speculated that oxLDL-derived superoxide contributes to the abundant level of
oxLDLs that build up in the arterial wall (Leopold and Loscalzo 2008; Ross et al. 2014).
It has been indicated that the genetic deletion (Judkins CP 2010) or pharmacological
inhibition (Nguyen-Khoa et al. 1999) of Nox can decrease the lesion formation in ApoE-/mice.
It has been previously demonstrated that increased risk for atherosclerosis is
gender or hormone dependent; for instance, Drummond et al. (2011) indicated that
premenopausal females have a lower propensity to develop CVD than their male or
ovariectomized female counterparts. These findings are relevant in the present discussion
because it was previously shown that elevated levels of estrogens, a sex hormone present
in higher amounts in premenopausal compared to postmenopausal women, could
modulate NADPH oxidase activity (Miller et al. 2007). Additionally, age contributes to
the accumulation of damaged DNA which can activate the transcription factor NF-κB
(Cheng et al. 2014). Circulating levels of pro-inflammatory cytokines and the endothelial
cell (EC) senescence increase with age (Cheng et al. 2014). Therefore, pharmacological
inhibition of NADPH oxidase may be an attractive strategy to reduce atherosclerosis in a
way that is not gender or age specific. Although it is generally accepted that
dyslipidemia contributes to atherogenesis, modulating metabolic pathways that regulate
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the inflammatory response requires further investigation. Therefore, this dissertation is
focused on the modulation of the endocannabinoid system as a means of atheroprotection
and understanding the mechanisms by which oxidative stress and endocannabinoids are
related.
2.3

Oxyradical stress, NADPH oxidase, Nrf2, and atherogenesis
Because of the unique chemistry of oxygen (O2) and its ability to harvest the rich

energy reserves found in nutrients, such as glucose and lipids, life is able to exist on our
planet. The ability of living organisms to use oxygen, however, has costs because ROS
are significant by-products of aerobic respiration. In some contexts, ROS have beneficial
properties that enable the innate immune system to confront microbial invaders. On the
other hand, excess ROS can result in macromolecule damage and cell death. Therefore,
excess ROS are important mediators of cellular and tissue injury, which in part
contributes to disease development. Oxidative stress has been implicated as a causative
factor in several diseases and aging (van der Loo B 2000; Hamilton et al. 2001; Hansson
et al. 2015). Because of the development of chemical tools that are used as selective
probes to detect and quantify specific ROS, such as superoxide and hydrogen peroxide,
the biochemical pathways that shape the landscape of oxidative stress in living cells are
becoming clearer (Brewer et al. 2015). This has enabled causal inferences instead of
mere associations to be made for specific oxyradical species in various physiological
processes, which has provided important insights into vascular biology and disease.
NADPH oxidase (Nox), xanthine oxidase, dysfunctional endothelial nitric oxide
synthase, cytochrome P450 monooxygenase, and lipoxygenase are found in vascular cells
and produce oxyradicals (superoxide) and oxy-nonradicals (hydrogen peroxide) either as
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primary products or as by-products of their enzymatic activity. The incomplete reduction
of oxygen during mitochondrial respiration also results in superoxide production. In
addition, myeloperoxidase catalyzes the reaction between hydrogen peroxide and
chloride, which generates the powerful oxidant hypochlorite (HOCl). These reactions are
described in Fig. 1. Nox is the only oxidoreductase that produces superoxide as its
primary end product, thus it was given the moniker “professional ROS producer” (Jiang
et al. 2011). Nox is typically inactive in circulating immune cells, such as neutrophils
and monocytes, but in the presence of pro-inflammatory cytokines, such as IL-1β and
TNF-α, it becomes activated. A multi-subunit complex is formed, which includes
membrane embedded Nox2-p22phox catalytic subunits and soluble regulatory subunits
p47phox, p67phox, p40phox, and Rho GTPase (Rac1 or Rac2), resulting in the assembly of
the Nox holoenzyme (Jiang et al. 2011). Active Nox catalyzes the one-electron reduction
of molecular oxygen by NADPH, forming superoxide. Superoxide has a limited
diffusion radius in the cell, because it is rapidly converted to hydrogen peroxide and
oxygen (dismutation) either spontaneously or via superoxide dismutase (SOD).
Furthermore, due to its negative charge, superoxide cannot passively diffuse through lipid
membranes as well as anion channels and aquaporins (Al Ghouleh et al. 2013). Although
superoxide per se is not reactive with cell macromolecules, SOD rapidly reduces its
concentration in cells, which is important because this minimizes the Fe3+-catalyzed
coupled reaction (Haber-Weiss) between superoxide and hydrogen peroxide that
produces hydroxyl radicals, hydroxide ion, and oxygen (Fig. 1). First, superoxide
donates an electron to Fe3+ to generate Fe2+ and O2, then hydrogen peroxide reacts with
Fe2+ to yield the hydroxyl radical and hydroxide ion (regenerating Fe3+, thus the net
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reaction is catalyzed by ferric ion). As compared with superoxide, the hydroxyl radical is
highly reactive and abstracts hydrogen atoms from proteins, DNA, and lipids (mainly
unsaturated fatty acids) in the vicinity of its production, thus generating more free
radicals and propagating oxidative stress (Ross et al. 2014).
Whereas excess concentrations of superoxide and ROS have obvious toxic
properties, these species also have fundamental roles in signaling pathways that enable
cells to adapt to stress (Kim and Byzova 2014; Lambeth and Neish 2014). There are
several different isoforms of Nox expressed in cells and these enzymes have important
roles in cellular homeostasis. For instance, macrophages express an abundant amount of
Nox2. Nox2 is activated in response to a variety of physiological stimulants such as
insulin, angiotensin II, and sheer stress. The superoxide that is generated can act as a
mild reductant because it surrenders an electron to an appropriate acceptor – for example,
it can either reduce Fe3+ to Fe2+ or a second molecule of superoxide to hydrogen
peroxide. Signaling pathways activated by superoxide-derived ROS include the stress
kinase ERK1/2, which is involved in cell differentiation; JNK-MAPK, which is involved
in the regulation of inflammation and cell death; NFκB, a transcription factor for
inflammatory and anti-apoptotic genes; Akt, which is involved in regulating metabolic
homeostasis; and Ras, Rac, and p38, which regulate several cellular functions such as
proliferation, apoptosis, and inflammatory gene expression (Hopkins 2013; Kim and
Byzova 2014). Nox2 is implicated in the development of atherogenesis and vascular
remodeling. For example, genetic deletion of Nox2 in the high-fat-diet-fed ApoE-/mouse model (ApoE-/-Nox2-/-) caused a reduction in atherosclerotic lesions compared
with control ApoE-/- mice (Lambeth and Neish 2014). This finding supports the notion
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that pharmacological inhibition of Nox might be an attractive strategy to reduce
atherosclerosis (Park et al. 2009; Park and Oh 2011; Mangum et al. 2015). In addition,
vascular endothelial growth factor-induced angiogenesis and neovascularization was
impaired in Nox2-/- mice, which implicates Nox2 in wound healing and the generation of
vessels (Judkins CP 2010).
A pathological consequence of the excess production of oxidants in the vascular
space is the buildup of oxidized low-density lipoproteins (oxLDL) and other oxidized
biomolecules in the intima of the vessel wall (Drummond et al. 2011). LDLs entrapped
in the intimal space are targets of oxyradical fluxes, leading to the chemical modification
of lipids and apoproteins in the LDL particle. The resulting oxLDL particles are a
hallmark lesion of atherosclerosis. Truncated oxidized phospholipids, such as
phosphatidylcholine (oxPCCD36), are detected in atherosclerotic plaques and in the
circulation of hyperlipidemic subjects (Tojo et al. 2005). Circulating monocytes then
migrate into the intimal space of the vessel wall and in the presence of macrophagecolony stimulating factor (M-CSF) can differentiate into macrophages. OxPCCD36
protrude from the surface of oxLDL like whiskers and their avid and specific interactions
with CD36 scavenger receptors promotes the uptake of oxLDL by macrophages and
smooth muscle cells, resulting in the uncontrolled uptake of toxic oxLDL particles and
the subsequent formation of foam cells (Griendling 2013; Ross et al. 2014). OxLDL
uptaken by macrophages is an unregulated process due to lack of negative regulation.
Consequently, macrophages take up massive quantities of cholesterol and become foam
cells. Upon phagocytosis of oxLDL, the store of cholesteryl esters that are abundant in
oxLDL are hydrolyzed to free cholesterol (FC) and free fatty acids inside the macrophage
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(Silverstein et al. 2010; Salomon and Gu 2011). The endoplasmic reticulum (ER) is
sensitive to the increased load of FC, which results in significant ER stress. The
signaling pathways activated by ER stress cause macrophage foam cells to undergo
apoptosis. Apoptosis and secondary necrosis of foam cells lead to development of
atherosclerotic plaques, which can result in acute thrombotic complications and death.
Despite abundant evidence to support the oxidative stress hypothesis of
atherosclerosis development, antioxidant approaches in human patients have been mostly
ineffective at reducing atherosclerosis. Thus, a greater understanding of the temporal and
spatial aspects of ROS production in the tunica intima during oxidative stress is needed.
Due to the large array of ROS and their limited lifetimes, it is difficult to pinpoint the
specific molecular and biochemical pathways that the oxyradicals perturb. However,
some key reactions are well known to contribute to atherogenesis. For example, excess
levels of superoxide that escape detoxication pathways can react with nitric oxide,
resulting in the depletion of this important vasoprotective, anti-inflammatory molecule
and the formation of the highly reactive oxidant peroxynitrite (Salomon and Gu 2011)
(Fig. 1). Chain reactions within lipid membranes initiated by oxyradicals results in
unrestrained lipid peroxidation reactions, which leads to the generation of electrophilic
α,β-unsaturated aldehydes (e.g. 4-hydroxynonenal, which is abbreviated 4-HNE),
aldehydes, and nitroalkenes (Ross et al. 2014). These reactive lipids are electrophiles
that can react either reversibly or irreversibly with nucleophiles in proteins and inhibit
their normal activities. The resulting “electrophilic stress” caused by lipid peroxidation is
implicated in atherogenesis (Feng et al. 2003).
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Cells have homeostatic mechanisms to control the concentrations of ROS and
electrophiles. For instance, glutathione (GSH) is a cysteine-containing tripeptide that
quenches intracellular ROS, forming oxidized GSSG in the process, and detoxifies
electrophiles (Mukhopadhyay et al. 2007; Heumuller et al. 2008; Judkins CP1 2010).
Furthermore, peroxidases, such as GSH peroxidase and peroxiredoxins, can detoxify both
hydrogen peroxide and organic peroxides. In addition, antioxidant concentrations in cells
can be increased by consumption of small biomolecules such as N-acetyl cysteine,
methionine, or polyphenolic compounds, thereby enhancing intracellular redox
homeostasis (Levonen et al. 2014). Although the biochemical pathways for removing
ROS and peroxides have been well characterized, chemopreventative strategies to
decrease the production of ROS that result from hypertension, hyperlipidemia, diabetes,
autoimmune, and inflammatory disease are still under investigation and a matter of
debate (Borazjani et al. 2011; Levonen et al. 2014).
Monocytes adhere to the endothelial cell layer of vessels via their interaction with
vascular cell adhesion molecules (VCAM), which are expressed on the endothelial cell
surface during inflammation. This causes the development of a positive feedback loop in
which NFκB signaling is activated in the endothelial cells, leading to further endothelial
cell dysfunction. The subsequent diapedesis of monocytes through the endothelial cell
layer and exposure to M-CSF causes the monocytes to differentiate into intimal
macrophages. The differentiation process can occur via classical activation (M1
phenotype), which requires pro-inflammatory stimulants such as interferon-γ and
lipopolysaccharide (LPS), resulting in the induction of TNF-α (Lambeth and Neish
2014). Alternatively, differentiation can occur via an activation pathway (M2 phenotype)
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in which macrophages are exposed to anti-inflammatory cytokines, such as IL-4 or IL-13,
which are associated with tissue repair (Levonen et al. 2014). Although M1 and M2 are
the best studied macrophage phenotypes in atherosclerotic plaques, Kuhn et al. (2011)
characterized a Mox phenotype that develops in response to electrophilic oxidized
phospholipids and involves the cellular electrophile sensor Nrf2-Keap1. The Mox
phenotype has aspects of both M1 and M2. The heterogeneity of macrophage phenotypes
found in atherosclerotic plaques has a major role in the inflammatory process, due to the
specific phenotype of the macrophage (M1, M2, or Mox) that contributes to the lesion
size, composition, and stability of the plaque (Baker et al. 2011). Nrf2 is a vital cellular
defense transcription factor that protects against the cytotoxic effects of oxidative and
electrophile stress. It is a member of the cap’ n-collar family and is a basic leucine zipper
transcription factor. Nrf2, under basal conditions, is negatively regulated in the
cytoplasm by the cysteine-rich Kelch-like ECH associated protein 1 (Keap1). However,
when cysteine residues in Keap1 are covalently modified by electrophiles (such as lipid
electrophiles) or oxidants, the Keap1-Nrf2 complex dissociates and Nrf2 translocates into
the nucleus where it binds to antioxidant response elements (AREs) in the 5’-regulatory
region of target genes, thereby initiating transcription (Fig. 3). OxPCCD36 and 4-HNE
each contain an ,-unsaturated aldehyde moiety, which is formed during lipid
peroxidation reactions. 4-HNE is a freely diffusible molecule, whereas oxPCCD36 is
associated with oxLDL particles. Both are electrophilic molecules that covalently modify
cysteines on Keap1, thereby stimulating Nrf2 transactivation activity (Johnson and
Newby 2009). Although several studies have described a role for PPAR- in regulating
CD36 gene expression (Gordon and Taylor 2005; Kuhn et al. 2011), it has also been
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shown that CD36 can be induced by oxPCCD36 and 4-HNE via Nrf2 activation (Adamson
and Leitinger 2011). Thus, Nrf2-mediated regulation of CD36 expression in
macrophages is a pathway distinct from that of PPAR-. Targeting the Nrf2 pathway
could be an attractive strategy for preventing foam cell formation and atherosclerosis.

Figure 2.1

Oxidative stress in vascular cells.

Nitric oxide (NO) and superoxide (O2.-) combine to make peroxynitrite (ONOO-) at a
rate that is diffusion-limited. Superoxide is rapidly metabolized by superoxide dismutase
present in mitochondria, cytoplasm, and extracellular space. Alternatively, xanthine
oxidase (XO) can produce superoxide as a byproduct of its activity. Superoxide (O2·-)
and hydrogen peroxide (H2O2) cross lipid membranes by either utilizing an ion channel
or passive diffusion. Activation of the CB1 receptor can enhance ROS and proinflammatory cytokine production. On the other hand, the activation of the CB2 receptor
is a protective mechanism due to the increased production of anti-inflammatory
cytokines.
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Figure 2.2

Nrf2 activation pathway.

Nrf2 is a member of the bZIP family of transcription factors. It is localized in the
cytoplasm under basal conditions by forming a complex with Keap1 and Cullin 3 until
activated. Under basal conditions, Nrf2 is ubiquitinated and degraded by proteosomes.
During electrophilic stress induced by oxLDL or 4-HNE, the cysteine residues in Keap1
are covalently modified leading to the subsequent ubiquitination of Keap1 and its
degradation. As Nrf2 builds up in the cytoplasm, it starts to translocate into the nucleus
forming a heterodimer with a Maf protein. The transcription factor complex associates
with antioxidant response elements (ARE) in upstream antioxidant genes to initiate
transcription. When NFκB forms a complex with IκB in the cytoplasm, it will be
ubiquitinated and degraded. However, when IκB is phosphorylated and degraded via the
ubiquitin-proteosome pathway, NFκB can translocate into the nucleus, it results in the
increased expression of genes that encode pro-inflammatory cytokines.
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2.4

Role of endocannabinoids in inflammation
In this section we briefly discuss the role of the endocannabinoids (eCBs) in

pathophysiological inflammation; however, for more detailed treatises of this subject, the
reader is directed to several excellent publications that describe the eCB system in depth
(Levonen et al. 2014). ECBs are arachidonoyl-containing lipids that are produced on
demand by the metabolism of glycerophospholipid precursors in cell membranes. The
best characterized eCBs are 2-arachdonoylglycerol (2-AG) and anandamide (AEA),
which are ligands for two G-protein coupled receptors termed cannabinoid (CB)
receptors 1 and 2. The eCBs are local-acting lipid hormones that act in an autocrine or
paracrine manner. The eCB ligands 2-AG and AEA are rapidly degraded by
hydodrolytic enzymes monoacylglycerol (MAGL) and fatty acid amide hydrolase
(FAAH) to its metabolites arachidonic acid and ethanolamide, respectively. The role of
the CB1 receptor in neurotransmission has been widely studied in the central nervous
system. The CB1 receptor was identified in the late 1980’s by isolating receptors in the
brain (Park et al. 2009). More recently these receptors have also been established as
having a role in the immune response and may contribute to the dysregulation caused by
high blood pressure and inflammation (Nagy et al. 1998; Adamson and Leitinger 2011).
The CB1 receptor is implicated in pro-oxidative stress/pro-inflammatory responses that
are associated with CVD (Ishii et al. 2004; Pacher and Steffens 2009; Mackie 2010;
Tanasescu and Constantinescu 2010; Booz 2011; Hopkins 2013). The CB2 receptor, on
the other hand, was cloned in the early 1990’s from rat spleen and was also detected in
the hematopoietic immune system (Devane et al. 1988). On the face of it, the CB1 and
CB2 receptors have similar biochemical functions; they are membrane-bound receptors
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coupled to a Gi/o-protein that when activated can inhibit adenylyl cyclase and modulate
calcium channel activity (Pacher and Steffens 2009). However, in contrast to CB1, the
CB2 receptor activation appears to block and modulate several pro-inflammatory effects,
suggesting that downstream signaling pathways evoked by the two receptors are
divergent. Several studies have demonstrated that ligand-mediated activation of the CB2
receptor can counter the inflammation found during oxidative stress (Mukhopadhyay et
al. 2007). For example, it can attenuate the following physiological and molecular
effects: inflammatory cell migration, endotoxin-induced oxidative stress, p38-MAPK
activation, and TNF-α secretion (Munro et al. 1993; Rajesh M1 2012). Nox activity was
also found to be attenuated by a CB2 agonist in human coronary artery EC (Mackie
2010). CB2 activation has also been shown to enhance HDL levels, thereby promoting
reverse cholesterol transport (RCT) (Pacher and Steffens 2009; Sugamura et al. 2010;
Turcotte et al. 2015). RCT is an important pathway by which non-esterified cholesterol
is effluxed from peripheral macrophages onto extracellular ApoA1 and mature HDL
acceptors for subsequent transport to the liver. Importantly, the de novo generation of
HDL particles via RCT helps to increase circulating HDL levels and reduce atheroma
development. ECBs are also vital in modulating immune cell proliferation and apoptosis,
cytokine production, macrophage-mediated phagocytosis, and inflammatory cell
migration during tissue injury (Booz 2011). Finally, the eCB ligand 2-AG has been
specifically implicated in the modulation of inducible nitric oxide synthase (iNOS), nitric
oxide (NO), and ROS production in immune cells (Turcotte et al. 2015).
Pharmaceutical targeting of the eCB system shows some promise. For instance,
the atherosclerotic lesion size decreased in the abdominal aorta of ApoE-/- mice treated
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with rimonabant, a CB1-specific antagonist (Rajesh et al. 2010). Pharmacological
blockade of the CB1 receptor or its genetic deletion also enhanced macrophage RCT via
ABCA1- and ABCG1-mediated cholesterol transport and reduced atherosclerosis
(Sugamura et al. 2010; Chouinard et al. 2011). Rajesh et al. (2010) demonstrated that
chemical blockade of the CB1 receptor could attenuate Nox expression, MAPK
activation, apoptosis, inflammation, ROS, and fibrosis. Whereas CB1 receptor activation
stimulates production of pro-inflammatory mediators, activation of CB2 receptors in
macrophages attenuated TNF-α production and evoked other anti-inflammatory
responses. Several studies have indicated that selective activation of CB2 may render
cardioprotective effects (Sugamura et al. 2010). For example, JWH-133, a CB2 agonist,
reduced superoxide generation, increased ERK 1/2 and STAT3 phosphorylation,
inhibited chemotaxis, and upregulated CD18/CD11b (CR3) expression on inflammatory
cells (Sugamura et al. 2010).
Therefore, in addition to endothelial dysfunction, hypertension, hyperlipidemia,
inflammation, and ROS, the eCB system also appears to be an important factor in
atherogenesis (Tsubakio-Yamamoto et al. 2008; Pacher and Steffens 2009; Pacher and
Kunos 2013). Although the specific mechanistic role of the eCB system in disease
development is still enigmatic, links have been postulated between the eCB system, Nox,
oxidative stress, and atherosclerosis (Rajesh M1 2012). Because of the large number of
oxyradical species that are produced in cells during vascular injury, which significantly
complicates the interpretation of experimental data, it is not a trivial task to identify the
pathophysiological pathways induced or enhanced by oxidative stress. Nevertheless,
several homeostatic mechanisms have evolved to protect against reactive small
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molecules, such as ROS and 4-HNE. For example, the enhanced biosynthesis of 2-AG
by cells that are “stressed” might be part of a compensatory protective mechanism, via
activation of the CB2 receptor by 2-AG and downstream signaling, that provides antiatherogenic effects.

Figure 2.3

2-Arachidonylglycerol biosynthesis and degradation in immune cells.

Phospholipids are metabolized into diacylglycerol (DAG) by phospholipase C-beta
(PLC-β). DAG is subsequently metabolized into 2-AG by the enzyme DAGLβ. 2-AG
can be degraded by either hydrolytic enzymes [carboxylesterase 1 (CES1), palmitoyl
protein thioesterase 1 (PPT1), or monoacylglycerol lipase] or oxidation [cyclooxygenases
(COX)]. COX1/2 metabolizes arachidonic acid (AA) into PG-G2, which are further
metabolized into PGH2 and prostaglandins. COX2, however, can metabolize AA into 11hydroxyeicosatetraenoic acid (11-HETE). Lipoxygenase (LOX) can metabolize AA into
metabolites 12-hydroxyperoxyeicosa-5,8,10,14-tetraenoic acid (12-HPETE) or 12hydroxyperoxyeicosa-5,8,10,14-tetraenoic acid (15-HPETE).
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2.5

Diacylglycerol lipase and Nox
Diacylglycerol (DAG) is a lipid and a second messenger molecule produced by

the enzyme phospholipase C-β (PLC-β) (Pacher and Mechoulam 2011; Pacher and Kunos
2013). DAG is hydrolyzed by sn-1-specific diacylglycerol lipases (DAGL) yielding the
endocannabinoid 2-AG (Fig. 2) in response to extracellular stimuli, including angiotensin
II, thromboxane A2, platelet activating factor, bradykinin, serotonin, glutamate, and
acetylcholine (Pacher and Steffens 2009; Pacher and Mechoulam 2011). Two isoforms
of DAGL (DAGL and DAGL) were identified in humans, on the basis of the
conservation of the intron-exon boundary in human DAGL isoforms with those in
Drosophila, fish, and rodents (Anilkumar et al. 2008; Mackie 2010). DAGL is found in
high concentrations in brain, whereas DAGL is found in high concentrations in immune
cells and macrophages (Signorello et al. 2011; Shonesy et al. 2015). Gao et al. (2010)
used DAGL-/- knockout mice to show that DAGLβ is a vital enzyme in the biosynthesis
of 2-AG. DAGL has four transmembrane (4TM) domains, a short cytoplasmic Nterminal sequence, a canonical α/β hydrolase domain that harbors the catalytic residues,
and several unconserved loops with potential sites for glycosylation (Astarita and
Piomelli 2009). DAGLβ can also be palmitoylated on a cysteine residue in a regulatory
loop (Reisenberg et al. 2012). Reversible fatty acyl-posttranslational modifications can
modulate protein-protein interactions, cellular trafficking, and substrate access.
The duration of the physiological response to endocannabinoids is regulated by
the balance of endocannabinoid biosynthetic and degradative pathways. AEA and 2-AG
are both degraded by hydrolysis, yielding arachidonic acid as a common metabolite and
ethanolamine and glycerol, respectively. In the mouse brain, ~85% of 2-AG hydrolytic
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activity is due to monoacylglycerol lipase (MAGL), with the remaining balance ascribed
to two hydrolytic enzymes, α/β-hydrolase domain (ABHD)-6 and ABHD-12 (Hsu et al.
2012). In addition, 2-AG and prostaglandin glyceryl esters (PG-Gs), which are
cyclooxygenase-derived oxygenated products of 2-AG, are also degraded by
carboxylesterase 1 (CES1) (Gao et al. 2010; Reisenberg et al. 2012). Further adding to
the list of hydrolytic enzymes that metabolize endocannabinoids, Wang et al. (2013)
identified palmitoyl protein thioesterase 1 (PPT1) as an enzyme that can hydrolyze 2-AG.
PPT1 is a monomeric lysosomal hydrolase known to hydrolyze thioester bonds that
attach long-chain fatty acids to cysteine residues (Blankman et al. 2007; Xie et al. 2010;
Carr et al. 2013).
DAG is also implicated in the regulation of Nox activity (Wang et al. 2013), thus
DAGL and DAGLβ are likely to be important hubs in this signaling pathway. Protein
kinase C (PKC) is recruited to lipid membranes by the presence of DAG and its kinase
activity is activated. This leads to the phosphorylation of the Nox regulatory subunit,
p47phox. Elevated concentrations of DAG cause a heightened oxidative response in cells
and this signal can be terminated by DAG kinase (Wang et al. 2013). DAGLβ also
appears to indirectly regulate the production of eicosanoids in the brain, liver, and
macrophages by increasing the levels of 2-AG in these tissues and cells (Wang et al.
2013). When 2-AG hydrolysis was blocked by either chemical inhibition of the principal
2-AG hydrolytic enzyme in brain, MAGL, or its genetic deletion, eicosanoid production
was also decreased and neuroinflammation was reduced in a mouse model (Lu and
Hofmann 2006). This is because the concentration of the cyclooxygenase substrate,
arachidonic acid, had been reduced.
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2.6

Conclusion
It now seems apparent that oxidative stress is both a cause and a consequence of

atherosclerosis. Superoxide and hydrogen peroxide are implicated in vascular
dysfunction through the initiation of diverse signaling and transcriptional pathways
(Schlam et al. 2013). There are arsenals of enzymes in cells that scavenge oxyradicals to
reduce the toxic burden of excess ROS. Emerging evidence indicates that the
endocannabinoids have the ability to reduce the production of inflammatory mediators in
the vascular wall as a compensatory response to oxidative stress. Pharmacological
inhibition or genetic blockade of the key biosynthetic enzyme DAGLβ reduces the
production of the eCB ligand 2-AG, indicating that DAGLβ is a key enzyme in
establishing the local eCB concentration, or “tone”, in a tissue or the vascular space.
Furthermore, Nox, the “professional ROS generator”, is a promising pharmacological
target due to the role it has in superoxide production and CVD pathology. Elucidation of
the physiological and pathophysiological processes emanating from Nox activation and
the role of eCB ligands in attenuating the inflammation and oxidative stress that result
from overactive Nox might be a beneficial treatment modality for CVD. Emerging
evidence indicates that the increase in local concentration of 2-AG is an adaptive
response to oxidative stress because of its antioxidant and anti-inflammatory activities.
Therefore, the genetic and lifestyle factors that lead to atherosclerosis development may
be counteracted by either increased biosynthesis (via increased DAGLβ activity) or
reduced hydrolysis (via decreased MAGL and/or other hydrolytic enzyme activities) of 2AG.
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CHAPTER III
OXIDIZED LOW DENSITY LIPOPROTEIN AND OXIDATIVE STRESS
3.1

Introduction
Atheromas in the vasculature are complex lesions comprised of lipids, necrotic

cells, cellular debris, and fibrous elements. A large number of studies have focused on
the mechanistic pathways of lipid entrapment within the intimal space resulting from
dysregulated lipid metabolism, in addition to reversing the narrowing vessel lumen.
Under basal conditions, the endothelium is protected against atherogenesis due to laminar
blood flow, high levels of superoxide dismutase, and genes pertaining to shear stress that
inhibit vascular cell adhesion molecule (VCAM) gene expression (Nomura et al. 2011;
Hsu et al. 2012). Alternatively, areas that are predisposed to lesion formation are sites of
branched arteries due to disrupted laminar blood flow. Endothelial cells begin to express
increasing amounts of VCAM-1 on the outer membrane when laminar flow is disrupted,
thereby recruiting monocytes into the intimal space (Nomura et al. 2011). In addition to
the upregulated expression of VCAM-1, P- and E-selectin are attracted to the vessel
causing the recruitment of monocytes leading to diapedeses and penetration into the
tunica intima. Within the intima, the monocytes undergo a morphological change and
differentiate into macrophages that express high numbers of scavenger receptors (SRA
and CD36) on their surface, which enables the internalization of glycated or oxidized
low-density lipoproteins (oxLDLs) (Kim and Byzova 2014).
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In this report, we will focus on CD36, a member of the SR-B1 family of
scavenger receptors, and the ability of oxLDL to act as a ligand for CD36 thereby
increasing NADPH oxidase activity. The general topography of CD36 is evolutionarily
conserved. It has 27-amino-acid hydrophobic transmembrane domains near the carboxylterminus and an uncleaved signaling peptide at the amino-terminus that includes an
uncleaved signal peptide that may potentially be a second membrane spanning domain
(Lambeth and Neish 2014). It functions in cholesterol uptake and also facilitates the
transfer of long-chain fatty acids into the cell via its fatty-acid translocase (FAT) activity
(Libby 2002). A range of diverse and pathologic processes are mediated by CD36
including energy metabolism via phagocytosis of long-chain fatty acids in adipocytes and
striated muscle cells, as well as phagocytosis of oxidized lipids in macrophages. It is
well established that macrophages engulf oxLDL in an unregulated manner leading to the
foam cell morphology and increased pro-atherogenic activities (Silverstein and Febbraio
2000). The localization of CD36 in the cholesterol rich microdomains could potentiate
its signaling and internalization functions, as well as the expression capacity increasing
with the differentiation of monocytes to macrophages in response to an influx of proatherogenic cytokines and increased exposure to LDL and oxLDL (Silverstein and
Febbraio 2000).
In macrophages, CD36 plays a major role in pro-inflammatory and proatherogenic signaling molecules that induces the intracellular migration of oxLDLs, in
addition to generation of ROS, upregulation of focal adhesion kinase (FAK), and
inhibition of SHP-2 (Silverstein and Febbraio 2000). Furthermore, platelet activation is
suggested to have a direct relationship with the response of CD36 to oxLDLs both in
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vitro and in vivo through NADPH oxidase-derived superoxide and reactive oxygen
species (Silverstein et al. 2010). The binding of oxLDL to CD36 induces a signaling
cascade that activates Src kinases, c-Jun N-terminal kinase and intracellular signaling that
activates the multi-subunit NADPH oxidase (Park et al. 2009; Moore and Tabas 2011;
Hopkins 2013; Ross et al. 2014; Silverstein 2015). The formation of the NADPH
oxidase complex through CD36-oxLDL binding is a significant source of oxidants in the
vessel wall leading to chemically reactive molecules migrating across the endothelium.
We hypothesize that the activation of NADPH oxidase is linked to enhanced
endocannabinoid tone (Chapter 4). It has been well established that the endocannabinoid
system is composed of two receptors (CB1 and CB2), their ligands and the enzymes that
degrade the ligands. Our group has demonstrated that activating the NADPH oxidase
complex via intracellular or extracellular-superoxide can increase 2-arachidonylglycerol
(2-AG) biosynthesis; which can be abrogated by chemically inhibiting the NADPH
oxidase (see Chapter 4). The aim of this study was to determine whether NADPH
oxidase activity increases following ligation of CD36 by oxLDL, thus providing the
oxidants needed to activate the synthesis of the endocannabinoid 2-AG. The mechanism
of NADPH oxidase activation (Nox2 isoform in macrophages) involves phosphorylation
of a cytosolic p47phox subunit and its subsequent translocation to membranes where Nox2
is found (Han et al. 1997). These studies used the human monocyte/macrophage cell line
HL-60 as a model because of its robust expression of Cd36 and Nox2 subunits (Park et
al. 2009; Silverstein et al. 2010).
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3.2
3.2.1

Materials and Methods
Chemicals and reagents.
Authentic standards of 2-AG, 2-AG-d8, and arachidonic acid (AA) were from

Cayman Chemicals (Ann Arbor, MI). O,O’-Diethyl p-nitrophenyl phosphate (paraoxon,
PO) was a kind gift from Dr. Howard Chambers (Mississippi State University). Avidinhorseradish peroxidase, N-acetyl cysteine (NAC), dimethyl sulfoxide (DMSO), trypan
blue solution (0.4% w/v), β-mercaptoethanol, phorbol 12-myristate 13-acetate (PMA),
fatty-acid free bovine serum albumin (BSA), penicillin, streptomycin, hydroethidine
(HE), and all buffer components were purchased from Sigma (St. Louis, MO). VAS2870, a selective Nox inhibitor, was purchased from Enzo Life Sciences (Farmingdale,
NY). Monoheptadecanoin (MHDG) internal standard, was purchased from NuCheck
(Elysain, MN). HyperSep Retain PEP column, BCA reagent and HPLC grade solvents
were purchased from Thermo-Fisher. FuGene 6 Transfection Reagent was purchased
from Promega Chemicals (Madison, WI). Plasmid Midi Kits were purchased from
QIAGEN. Human DAGLβ plasmid was purchased from Origene (Bethesda, MD). Antihuman DAGLβ (ab103100) and anti-V5 tag (ab 182008) antibodies were purchased from
Abcam (Cambridge, MA). Goat anti-rabbit IgG and goat anti-mouse IgG antibodies were
purchased from Cayman Chemicals. Acetylated oxidized (ox)LDL were from Intracel
(Bethesda, MD). Primers for diacylglycerol lipase beta (DAGLβ), CB1, CB2, p47phox,
NOX2, GAPDH, and CD36 were purchased from Invitrogen.
3.2.2

Cells, culture conditions and stimulation.
Human HL-60 cells, THP-1 cells, COS-7 cells, RPMI-1640 medium with and

without phenol red (containing 2 mM L-glutamine, 10 mM HEPES, 1 mM sodium
43

pyruvate, 4500 mg/L glucose and 1500 mg/L sodium bicarbonate) were purchased from
the American Type Culture Collection (ATCC) (Manassas, VA). Fetal bovine serum
(FBS) was purchased from Invitrogen (Grand Island, NY). THP-1 monocytes were
passaged in RPMI-1640 containing 10% FBS and 50 µg/mL gentamicin (complete
medium) (Magwenzi et al. 2015). COS-7 cells were passaged in DMEM medium
containing 10% FBS and 10 units/mL penicillin and 10 µg/mL streptomycin (complete
medium) (Magwenzi et al. 2015; Silverstein 2015). HL-60 cells were passaged in RPMI1640 containing 10% FBS 10 units/mL penicillin and 10 µg/mL streptomycin (complete
medium). Cells were cultured at 37°C in an atmosphere of 95% air/5% CO2. HL-60 and
THP-1 cells were differentiated into macrophage-like cells by adding PMA to the culture
medium (final concentration 100 nM) and growing the cells for 72 h.
A human DAGLβ expression plasmid (Origen) was transformed into One-Shot
Top10 chemically competent E. coli and the cloned plasmid was purified using QIAGEN
Plasmid Midi Kit following the manufacturer’s instructions. COS-7 cells were
transfected with either human DAGLβ cDNA or empty plasmid (control) using the
FuGene 6 Transfection Reagent in Opti-MEM medium and the transfected cells
incubated overnight. The transfection medium was removed and replaced with fresh
(complete) DMEM medium.
3.2.3

Preparation of cell lysates.
THP-1 monocytes were collected by centrifugation (1000 x g for 5 min), washed

with cold phosphate-buffered saline (PBS), resuspended in ice-cold 50 mM Tris-HCl
buffer (pH 7.4), and lysed by sonication (three 15 s bursts on ice at 30% maximum
power). THP-1 macrophage monolayer (~80-90% confluent) were washed with cold
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PBS, scraped into ice-cold 50 mM Tris-HCl (pH 7.4) buffer, and sonicated. COS-7 cells
transfected with DAGLβ and control COS-7 cells were harvested with 2 mL Accutase for
5 min. Fresh DMEM containing 10% FBS was added to stop the Accutase reaction. The
detached cells were pelleted at 1000 x g (5 min), washed 3 times with sterile PBS,
resuspended in ice-cold 50 mM Tris-HCl (pH 7.4) buffer, and sonicated. Protein
concentrations of the cell lysates were determined using the BCA reagent according to
the manufacturer’s instructions (Thermo-Fisher). Cell lysates were used fresh or flash
frozen and stored at -80°C prior to use.
3.2.4

Macrophage CD36 expression and NADPH oxidase activity.
The expression of CD36 was determined using RT-PCR. Functional studies

examining oxLDL uptake was determined by utilizing oxLDLs and controls were treated
in same manner, without oxLDL. NADPH oxidase was first inhibited in the
macrophage-like HL-60 cells by pre-incubating the cells in plain RPMI -1640 containing
10 μM VAS-2870 for 30 min. Subsequently, the macrophage were incubated for 24 h
with 50 µg/mL oxLDL followed by 10 incubation with 3.2 µM PMA. COS-7 cells were
transfected as previously described. Because NOX2 and p47phox are the catalytic subunits
of NADPH oxidase, and DAGLβ is a second messenger in the biosynthesis of 2-AG, RTPCR was done to measurement their mRNA expression levels to determine whether
NADPH oxidase is modulated in CD36-oxLDL induced superoxide production.
3.2.5

2-Arachidonoylglycerol biosynthesis by HL-60 cells.
Macrophages were incubated in serum-free medium with 10 µM VAS-2870 for

30 min prior to stimulation, to inhibit NADPH oxidase. Nox was activated via the
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addition of PMA (3.2 µM) for 30 min at 37°C. The macrophages were washed in
phosphate buffered saline (PBS), scraped in 50 mM Tris-HCl buffer, transferred into
microcentrifuge tubes, and sonicated 3 times for 15 sec at 30% power. The oxyradical
probe HE (20 μM final concentration) was added to the cells and incubated for an
additional 20 mins. The cells were washed, collected in 300 μL of 1:1 methanol: water,
centrifuged for 5 min at 16,000 rpm, and supernatant was collected for UPLC analysis to
determine the rate of 2-OH-Et+, the specific oxidative product of HE. The culture
medium was collected to measure the production of 2-AG. For 2-AG analysis, chemical
reactions were quenched with the addition of 2 volumes ethyl acetate containing 0.1%
acetic acid with deuterated 2-AG (internal standard). The samples were vortexed for 1
min and centrifuged at 3,000 x g for 5 min. Alternatively, HL-60 cells were pre-treated
with VAS-2870 (10 µM) for 30 mins followed by the addition of 3.2 µM PMA (10 min).
The samples were extracted using HyperSep Retain PEP columns. The column was
activated on vacuum with 2 mL ethyl acetate followed by 4 mL methanol; 2 mL of 95:5
water: methanol containing 0.1% acetic acid was added to equilibrate. The culture
medium was collected and loaded to the column. MHDG was spiked in as internal
standard. The column was eluted into a clean glass centrifuge tube with 0.5 mL of
methanol followed by 2 mL ethyl acetate. The organic solvent was dried under nitrogen,
and resuspended in 1:1 methanol: water for UPLC analysis.
3.2.6

Quantitative real-time PCR.
The SMCs RNA was isolated using RNeasy Plus Mini Kit according to the

manufacturer’s instructions. NanoDrop ND-1000 spectrophometer (Thermo Scientific,
Walham, MA) was used to quantify recovered RNA followed by cDNA synthesis using
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iScript Select cDNA Synthesis Kit (BioRad) according to manufacturer’s instructions.
Real-time PCR of cDNA was performed on a Stratagene Mx3005P thermocycler with
Quantifast SYBR Green PCR master mix from Qiagen. Primers are detailed in Table 3.1.
The cycle program used for all target genes consisted of 5 min hot start at 95°C prior to
10 s at 95°C for 40 cycles, followed by 30 s at 60°C. The dissociation curve was
generated for PCR product quality immediately after analysis. Expression differences
were normalized using GAPDH and quantified using the ΔΔCT method. The results
generated were in fold differences of gene expression.
Table 3.1

Primer sequence used for quantitative real-time PCR

Gene
(Homo
sapien)
CB1
CB2
NOX2

Forward Sequence

Reverse Sequence

CAACAAGTCTCTCTCGTCCT
CACTGATCCCCAATGACTAC
CGAAATGATGGTGACTGGCT

GATGAAGTGGTAGGAAGGC
CCACTCCGTAGAGCATAGAT
CCCAGCCAGTGAGGTAGATGT

P47phox

ATTCACAAGCTCCTGGACGG

ACACGTCTTGCCCTGACTTT

DAGLB

Hs_DAGLB_1_SG QuantiTect Primer Assay – QT00074319

GAPDH

Hs_GAPDH_1_SG QuantiTect Primer Assay – QT00079247

3.2.7

LC-MS/MS analysis.
2-AG analysis was performed on an UPLC-MS/MS system (Waters Acquity

UPLC interfaced with a Thermo Quantum Access Max triple quadrupole mass
spectrometer) using the method described by Wang et al. (Mangum et al. 2015). Extracts
were injected (10 μL) onto an Acquity UPLC BEH C18 column (2.1 mm × 100 mm, 1.7
μm) equipped with a VanGuard pre-column (2.1 mm × 5 mm, 1.7 μm) at 40°C using
column oven. For 2-AG, 2-AG-d8 and MHDG, the mobile phases were a blend of
47

solvent A (0.1% (v/v) acetic acid in water) and solvent B (0.1% (v/v) acetic acid in
methanol). The elution program was described previously (Gaut and Carchman 1987;
Ricciarelli et al. 2000) and the flow rate was 0.2 mL/min. The column eluate was
directed into the mass spectrometer using heated electrospray ionization in the positive
ion mode. Single-reaction monitoring (SRM) of analytes were: 2-AG, [M+H]+
m/z 379.2>287.2; 2-AG-d8, [M+H]+ m/z 387.2>295.2; MHDG, [M+H]+
m/z 344.8>326.8. The internal standard 2-AG-d8 or MHDG were used for quantification.
MS parameters were set as follows: spray voltage = 3500 V, vaporizer temperature =
350°C, sheath gas = 25 units, auxiliary gas = 2 and capillary temperature = 350°C. Scan
times were 0.2 s per SRM and the scan width was m/z=0.01. Collision energies and the
tube lens voltage were optimized using autotune software for each analyte by postcolumn infusion of the individual compounds into a 50%A/50%B blend of the mobile
phase being pumped at a flow rate of 0.2 mL/min. Xcalibur software was employed for
data acquisition and processing.
3.2.8

Statistical analyses.
Data are expressed as means ± SD. Statistical significance between two groups

was determined by Student’s t-test. Statistical significance between more than two
groups of data were compared by one-way ANOVA (Student-Newman-Keuls method).
Values of p < 0.05 were considered to be significant.
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3.3
3.3.1

Results
Macrophage CD36 expression and NADPH oxidase activity.
Our lab previously reported that COS-7 cells overexpressing human DAGLβ

treated with arachidonic acid had the ability to increase the production of 2-AG, which
could be abrogated upon treating the cells with either a Nox or DAGLβ inhibitor (Chapter
4). These data extended previous reports by demonstrating a vital role for DAGLβ in the
synthesis of the anti-inflammatory cannabinoid receptor ligand 2-AG following the
activation of NADPH oxidase (Figure 3.1 A).
RT-PCR data revealed an increase in mRNA expression of DAGLβ and the
NADPH oxidase regulatory subunit, p47phox, but not NOX2, when HL-60 cells were
exposed to oxLDLs (Figure 3.1 B). It is well documented that the CB1 receptor
contributes to the inflammatory response seen with the influx of oxidative stress, whereas
the CB2 receptor plays a role in anti-inflammatory responses. Therefore, we used
oxLDL-treated HL-60 macrophage-like cells and measured the mRNA levels of the CB
receptors to determine whether the treatment would modulate the CB receptor expression
(Figure 3.1 C). The data revealed an increased expression of both CB1 and CB2 when
treated with oxLDL as compared with the control group, although the upregulation of
CB2 was less marked than for CB1.
3.3.2

Role of carboxylesterases in human DAGLβ overexpressing cells.
Because 2-AG acts locally and is rapidly degraded by hydrolytic enzymes (Wang

et al. 2013), we determined the JZL184-inhibitable level of para-nitrophenyl valerate
(pNPV) hydrolysis activity in the HL-60 cell line, which represents the carboxylesterase
(CES) activity. We observed that roughly 50% of the pNPV hydrolysis activity in the
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HL-60 cells was inhibited by JZL184 (Figure 3.2A), indicating the proportion of pNPV
hydrolysis activity that is attributable to CES in the HL-60 cell line. In a subsequent
experiment, we treated COS-7 cells overexpressing human DAGLβ with either PO or
CPO to inhibit eCB hydrolytic activity (Wang et al. 2013), to prevent the degradation of
2-AG. Treatment with both inhibitors significantly increased the level of 2-AG
compared to DMSO treated controls (Figure 3.2 B,C).
3.3.3

PMA-induced 2-arachidonylglycerol biosynthesis.
Superoxide is increased following stimulation of HL-60 macrophage-like cells

with phorbol ester. Levels of superoxide, as measured using the surrogate compound 2OH-Et+, which is the specific superoxide-derived oxidized product of the HE probe, were
increased after incubations of cells with PMA (Figure 3.3A). Furthermore, the formation
of the Nox holoenzyme is a complex pathway that can be influenced by an array of
biochemical events, including the liberation of arachidonic acid by phospholipase A2 to
promote the conformational changes of p47phox that activate it (Figure 3.3 B). In
addition, oxLDL can potentially enhance the biosynthesis of 2-AG, thus increasing the
endocannabinoid concentrations in macrophages (Figure 3.6).
To understand the role that NADPH oxidase plays in the production of
oxyradicals and 2-AG biosynthesis, we examined whether PMA-induced oxidative stress
could be blocked by inhibiting the formation of the Nox subunits. First, we treated
macrophage-like HL-60 cells with oxLDL to determine whether DAGLβ protein
expression would increase. The western blot analysis revealed an increased band
intensity for DAGLβ protein in the oxLDL-treated cells compared to untreated cells
(Figure 3.4). We treated cells with PMA in the presence or absence of a Nox inhibitor
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and demonstrated that PMA could increase the amount of superoxide produced (as
measured by 2-OH-Et+) (Figure 3.5A). Further, 2-AG biosynthesis was also abrogated
by addition of the Nox inhibitor (Figure 3.5 B).

Figure 3.1

oxLDL induced mRNA of DAGLβ, Nox subunits, and cannabinoid
receptors.

(A) Scheme of oxLDL binding CD36 to stimulate the NOX2. NOX2 activation leads to
the production of ROS enhancing human DAGLβ expression, the second messenger 2AG production. This mechanistic pathway potentiates anti-atherogenic effects through
the upregulation of CB2 receptor. (B) HL-60 cells were differentiated into macrophages
by PMA (100 nM, 72 h) then treated with oxLDL (50 µg/mL for 24 h) or left untreated.
The levels of NOX2, p47phox, and DAGLβ mRNA were determined in each group. Data
represents mean ± SD n=3. * p<0.05, Student’s t-test.
OxLDL, Oxidized low density lipoprotein; NOX2, NADPH oxidase; ROS, reactive
oxygen species; DAGLβ, diacylglycerol lipase-beta; PMA, phorbol 12-myristate 13acetate; CB, cannabinoid.
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Figure 3.2

HL-60 cells have the biochemical machinery to produce 2-AG which can
be hydrolyzed by serine hydrolases.

(A) Activity progress curve for the hydrolysis of pNPVa by CES. HL-60 cells were
treated with [0-10 µM] JZL184 for 30 mins followed by pNPVa hydrolysis assay. CES
activity was monitored for 5 min at 37°C. The pNPVa was nearly completely hydrolyzed
by the CES enzymes. (B) Human DAGLβ overexpressed COS-7 cells lysate (0.25
mg/mL) was incubated with CPO (0.1 µM) for 30 min. The reaction was quenched with
two volumes of ethyl acetate containing 0.1% acetic acid doped with 2-AG-d8, and the
organic layer was collected and dried under nitrogen. The residue was re-suspended in
1:1 (v/v) methanol/water to quantify 2-AG levels by LC-MS/MS. (C) Human DAGLβ
cells lysate (0.25 mg/mL) was incubated with PO (50 µM) for 30 min and extracted as
described above. These data demonstrated a significant increase in 2-AG biosynthesis in
the presence of the serine hydrolase enzymes that degrade 2-AG. Data represents mean ±
SD n=3. * p<0.05, Student’s t-test.
Para Nitrophenyl valerate, pNPVa; carboxylesterase, CES; chlorpyrifos oxon, CPO; 2arachidonylglycerol, 2-AG; paraoxon, PO.
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Figure 3.3

Human THP-1 macrophages treated with PMA or oxLDL increased the
production of superoxide.

Treatment of THP-1 macrophages PMA (A) and oxLDL (B) heighted the production of
2-OH-Et+, the specific oxidative product of hydroyethidine (HE) compared to the control.
(C) Scheme describing the activation of the Nox multi-subunit complex in cells. Several
biochemical events converge to increase Nox activity. These include arachidonic acid
(AAi) being liberated inside the cell by the action of phospholipase A2 (PLA2) on
glycerophospholipids, which activates protein kinase C (PKC) and promotes
conformation changes in p47phox; small G-protein Rac activation; and diacylglycerol
(DAG)-mediated PKC activation, which results in the phosphorylation of p47phox (PMA
mimics the stimulatory effects of DAG on PKC activity). The output of these various
steps results in the functional activation of the catalytic Nox2 subunit. This permits the
transfer of 2 electrons from NADPH to the FAD co-factor and the sequential one-electron
reduction of two heme moieties, resulting in one-electron reductions of molecular oxygen
to yield superoxide anion. Data represents mean ± SD n=3. * p<0.05, Student’s t-test.
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Figure 3.4

OxLDL induced the expression of the key 2-AG biosynthetic enzyme
DAGLβ.

HL-60 cells were differentiated to macrophage like cells with PMA (100 nM). The
macrophage-like cells were challenged with oxLDL (50 µg/mL) for 24 h exhibited an
increase DAGLβ protein expression in oxLDL treated cells compared with non-oxLDL
treated controls.
Diacylglycerol lipase beta, DAGLβ; oxidized low density lipoprotein, oxLDL.

54

Figure 3.5

PMA-induced superoxide are dependent on Nox activity.

The superoxide-specific product 2-OH-Et (A) and 2-AG (B) levels were significantly
higher in HL-60 cells treated with 0.32 µM of PMA, but these data were significantly
abrogated with the addition of 10 µM Nox inhibitor, VAS2870. Data represents mean ±
SD n=3. * p<0.05 relative to vehicle control; # p<0.05 relative to PMA–treated cells,
one-way ANOVA (Student-Newman-Keuls method).
Oxidized low density lipoprotein, oxLDL; 2-hydroxyehtidium, 2-OH-Et+; NADPH
oxidase, Nox.
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Figure 3.6

Scheme representing pro-inflammatory cascade.

LDL become oxLDL with a high affinity for CD36. The CD36-oxLDL complex activate
Nox leading to enhanced ROS. With eCB ligands having equal affinity for both
receptors, the pathway can lead to either be pro- or an anti-inflammatory.
(Oxidized) Low density lipoprotein, (ox)LDL; NADPH oxidase, Nox; reactive oxygen
species, ROS; (endo)cannabinoid, eCB; diacylglycerol lipase beta, DAGLβ,
cyclooxygenase, COX; prostaglandin, PG; 2-arachidonylglycerol, 2-AG; arachidonic
acid, AA; ATP binding cassette A1, ABCA1; apolipoprotein A1, ApoA1;
carboxylesterase, CES; monoacylglycerol lipase, MAGL; peroxisome proliferatoractivated receptor gamma, PPARγ; liver X receptor alpha, LXRα.
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3.4

Discussion
The formation of lipid-laden foam cells is hallmark in the pathophysiology of

atherosclerosis. The recruitment of monocytes to the intima and the subsequent
internalization of oxLDL leads to chronic inflammation within the vessel wall.
Numerous studies have elegantly described the multiplicity of CD36 functions in
response to oxLDL and other mediators due to the inverse relationship between CD36,
the principal receptor for cellular cholesterol influx, and ABCA1, a key transporter in
cholesterol efflux. An upregulation in PPARγ receptor, which leads to increased CD36
expression, causes a feed-forward action on PPARγ. Macrophage uptake of oxLDL via
the upregulation of scavenger receptor CD36 can indeed lead to enhanced oxidative stress
in phagocytic cells (Wang et al. 2013). Further in a study by Jiang et al (2009) using the
non-specific cannabinoid agonist WIN 55,212-2 it was shown that the PPARγ receptor
was upregulated, thereby increasing CD36 expression. However, the levels of ABCA1
expression was significantly reduced in the presence of the CB1 antagonist AM251. Our
lab expounded on these data using menadione, a redox cycling agent that produces
superoxide, in J774A.1 macrophages. Levels of superoxide following treatment of WIN
55,212-2 were reduced (Chapter 4).
Studies have been conducted as to the role of the cannabinoid system during
atherogenesis. There is emerging evidence that chronic low doses of Δ9tetrahydrocannabinol (THC), the active component of marijuana, can potentially inhibit
the progression of atherosclerotic lesions through interactions involving interferon
gamma and decreased macrophage infiltration into the intimal space (Steffens et al. 2005;
Jiang et al. 2009). However, there is conflicting data for THC. THC can reduce in
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lymphoid cell proliferation, infiltration of macrophages, and interferon gamma secretion,
which are characteristics of atheromas (Jiang et al. 2009). On the other hand, Chen et al
(2015) reported that interferon gamma was enhanced by THC in the C57BL/6 mouse
model, but whether this effect was mediated via the CB1 and/or CB2 receptors was
unclear. The endogenous ligand 2-AG is thought to be an athero-protective by means of
downregulating pro-inflammatory cytokines including tumor necrosis factor-alpha (TNFα), IL-1β, and monocyte chemoattractant protein-1 (MCP-1), while upregulating
CD18/CD11b (CR3) (Pacher and Steffens 2009). There is a large body of literature
suggesting that 2-AG biosynthesis and the upregulation of CB2 receptor levels has the
ability to reduce atherosclerotic lesions in vessels. Here we demonstrated enhanced levels
of 2-AG and increased CB1 and CB2 receptor expression, in the presence of oxLDL.
Furthermore, when RAW264.7 macrophages were incubated for 24 h with >5 μM of the
non-selective CB agonist WIN 55,212-2, the levels of PPARγ were markedly increased
(Jiang et al. 2009). In agreement with those findings, our data suggest that the oxLDL
have the capacity to stimulate the production of oxyradicals leading to the biosynthesis of
2-AG. To support our work on NADPH oxidase leading to enhanced biosynthesis of 2AG (Chapter 4), we examined whether inhibiting NADPH oxidase would modulate the
endocannabinoid system and whether this is a protective response against intracellular
oxidative stress. HL-60 cells are widely used in oxyradical studies because they have an
abundance of NADPH oxidase (Gaut and Carchman 1987). We demonstrated in this
study using this cell line, that the mRNA expression of components of the NADPH
oxidase complex was increased when stimulated with PMA, which could be abrogated
when NADPH oxidase was inhibited. Similarly, THP-1 and J774A.1 cells pre-treated
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with PO or CPO following treatment with PMA expressed similar results (Chapter 4)
(Wang et al. 2013).
The most effective therapeutic strategies for CVD targets risk factors such as
hypertension with the use of angiotensin II receptor antagonist or hypercholesterolemia
with statins. Although both these pharmaceutical regimens have their benefits,
alternative methods to reduce the prevalence of CVD are needed. Targeting the
endocannabinoid system is an emerging strategy to reduce chronic inflammation that
leads to atherosclerosis. It has been well documented that increasing the CB2 receptor
(Booz 2011) and decreasing the CB1 receptor (Pacher and Steffens 2009) on innate
immune cells can block the production of pro-inflammatory mediators and decrease the
occurrence of reactive oxygen species. Although more research is necessary to detail the
specific pathways of activation, we have identified that CD36-oxLDL-evoked signaling
results in increased levels of reactive oxygen species activation of the Src kinase family,
PKC and the NADPH oxidase (Magwenzi et al. 2015). This study provided insight into
the role of CD36-oxLDL modulation of the endocannabinoid 2-AG. Since oxLDL can
lead to the phosphorylation of p47phox in a Src-CD36-dependent manner (Magwenzi et
al. 2015), increased CD36 receptor expression can indeed correlate with increased foam
cell formation. 2-AG has the ability to modulate intracellular oxidation and inflammation
associated with the pathophysiology of atherogenesis to maintaining balance within the
cardiovascular wall.
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CHAPTER IV
HEIGHTENED OXYRADICAL STRESS IN MACROPHAGES INCREASES
BIOSYNTHESIS OF THE ENDOCANNABINOID 2ARACHIDONOYLGLYCEROL
4.1

Introduction
The development of cardiovascular disease (CVD) is caused by several

environmental, genetic, and lifestyle factors (Libby et al. 1997). Atherosclerosis is a
primary cause of CVD and is due to altered homeostatic processes that regulate lipid
metabolism and inflammation (Ross et al. 2014). Initiating events that contribute to the
development of atherosclerosis include endothelial dysfunction, hypertension,
hyperlipidemia, and inflammation (Ross et al. 2014). The resulting pathology leads to
the overproduction of reactive oxygen species (ROS) that chemically modify entrapped
low-density lipoproteins (LDL), yielding toxic oxidized (ox)LDL. The danger-associated
molecular patterns revealed on the oxLDLs can be recognized by scavenger receptors on
intimal macrophages, enabling the phagocytosis of these cholesterol-enriched particles
and development of macrophage foam cells (Moore and Tabas 2011). Thus, an
imbalance in ROS biosynthesis and catabolism in vascular wall cells results in significant
oxidative stress and is an important contributor to disease.
ROS, such as superoxide (O2.-) and hydrogen peroxide (H2O2), are produced in
most cell types in the vessel wall in response to a variety of external stimuli, including
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nitric oxide, oxLDL, shear stress, and angiotensin II. These stimuli activate several ROSgenerating enzymes including NADPH oxidase (Nox), cyclooxygenase, lipoxygenase,
xanthine oxidase, uncoupled nitric oxide synthase, and myeloperoxidase, resulting in
significant oxidative stress (Booz 2011; Griendling 2013; Ross et al. 2014). The elevated
levels of ROS also cause a buildup of oxLDL levels in the vessel wall and the influx of
monocytes and neutrophils from the blood stream, resulting in a detrimental
inflammatory feedback loop. The increased flux of oxyradicals and the peroxidation of
extracellular LDL is a hallmark of atherosclerosis.
OxLDL can stimulate CD36 scavenger receptor-evoked signal transduction
pathways in macrophages and platelets, leading to the activation of Nox and the synthesis
of superoxide (Miller et al. 2010; Rajesh et al. 2010; Park et al. 2011; Magwenzi et al.
2015). Nox is a multisubunit holoenzyme that catalyzes the transfer of electrons from
NADPH to molecular oxygen (Lambeth et al. 2007). This results in the production of
superoxide, which has a limited ability to diffuse through the cell but can cross lipid
membranes via anion channels. Superoxide rapidly dismutates to H2O2, which has a
more tempered reactivity and greater diffusion radius compared to superoxide. Because
H2O2 is not charged, it is capable of moving through lipid membranes via passive
diffusion. The overactivation of Nox can be countered by several compensatory
mechanisms, including detoxification of excess superoxide by superoxide dismutase
(SOD) (Ross et al. 2014), activation of endoplasmic reticulum stress-induced apoptotic
pathways (Feng et al. 2003), and possibly by the endocannabinoid system (Sugamura et
al. 2010).
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The endocannabinoid (eCB) system is comprised of several components. These
include two G protein-coupled receptors, CB1 and CB2, which are mainly expressed in
the central nervous system and hematopoietic system, respectively. The CB receptors are
activated by endogenous arachidonoyl-containing ligands 2-arachidonoylglycerol (2-AG)
and anandamide (AEA). Diacylglycerol lipase (DAGL)α and  are the rate-limiting
enzymes involved in the biosynthesis of 2-AG in the brain and macrophages, respectively
(Hsu et al. 2012), while monoacylglycerol lipase (MAGL) is the primary enzyme that
degrades 2-AG (Blankman and Cravatt 2013). The CB1 receptor has important roles in
neurotransmission in the central nervous system; whereas, the CB2 receptor has an
immunomodulatory function in peripheral immune responses. Activation of CB2 can
attenuate the following immune processes in macrophages: (i) inflammatory cell
migration and endotoxin-induced oxidative stress (Booz 2011), (ii) activation of Nox
(Horvath et al. 2012), and (iii) p38-MAPK activation and TNF-α production (Pacher and
Steffens 2009; Hao et al. 2010; Rajesh et al. 2010; Hopkins 2013). Furthermore,
increased biosynthesis of 2-AG and evoked CB2 receptor-dependent signal transduction
pathways have been associated with the amelioration of atherosclerotic lesions in a
mouse model (Sugamura et al. 2010). It was also shown that cultured macrophages
exposed to oxLDL can produce greater quantities of 2-AG and AEA (Jiang et al. 2009).
Thus, the endocannabinoid system plays an important role in macrophage function;
however, there is a gap in knowledge regarding the specific pathways that lead from
exposure to oxLDL to the increases in endocannabinoid levels.
Because it is known that exposure to oxLDL results in increased ROS production
by macrophages, the purpose of this study was to explore whether (and how) the
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endocannabinoid system becomes activated in macrophages in response to acutely
elevated superoxide levels (and heightened Nox activity). Specifically, the levels of 2AG and AEA were determined following treatments of cultured macrophages with either
an extracellular superoxide generating system (xanthine oxidase) or with Nox stimulators
(phorbol ester and arachidonic acid). A large body of evidence has suggested that
activation of the CB2 receptor can render cardioprotective effects (Pacher and Steffens
2009; Hao et al. 2010; Rajesh et al. 2010; Hopkins 2013); therefore, enhanced 2-AG
levels may be part of a compensatory mechanism to activate anti-inflammatory and antioxidative pathways within vascular cells. We have addressed this issue by inducing high
levels of oxidative stress in cells using a redox cycling agent (menadione) and examining
the effects of a non-selective cannabinoid receptor agonist (WIN 55,212-2). In this
report, we show that oxyradical stress in macrophages increases the biosynthesis of 2-AG
in both human and mouse macrophage cell lines and in a cell line engineered to
overexpress DAGL. Moreover, we showed that WIN 55,212-2 can partly attenuate the
oxidative stress induced by menadione.
4.2
4.2.1

Materials and Methods
Chemicals and reagents.
Authentic standards of 2-AG, 2-AG-d8, arachidonic acid (AA), 1-stearoyl-2-

arachidonoylglycerol (SAG), WIN 55,212-2, AM630, and rimonabant were from
Cayman Chemicals (Ann Arbor, MI). O,O’-Diethyl p-nitrophenyl phosphate (paraoxon,
PO) was a kind gift from Dr. Howard Chambers (Mississippi State University). Avidinhorseradish peroxidase, dimethyl sulfoxide (DMSO), lactate dehydrogenase (LDH),
xanthine and xanthine oxidase, trypan blue solution (0.4% w/v), β-mercaptoethanol,
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phorbol 12-myristate 13-acetate (PMA), fatty-acid free bovine serum albumin (BSA),
penicillin, streptomycin, menadione (MD), hydroethidine (HE), ionomycin, apocynin,
U73122, Orlistat, and all buffer components were purchased from Sigma (St. Louis,
MO). VAS-2870, a selective Nox inhibitor, was purchased from Enzo Life Sciences
(Farmingdale, NY). BCA reagent and HPLC grade solvents were purchased from
Thermo-Fisher. FuGene 6 Transfection Reagent was purchased from Promega
Chemicals (Madison, WI). Plasmid Midi Kits were purchased from QIAGEN. Human
DAGLβ plasmid was purchased from Origene (Bethesda, MD). Anti-human DAGLβ
(ab103100) and anti-V5 tag (ab 182008) antibodies were purchased from Abcam
(Cambridge, MA). Goat anti-rabbit IgG and goat anti-mouse IgG antibodies were
purchased from Cayman Chemicals. Acetylated (ac)LDL and oxLDL were from Intracel
(Bethesda, MD).
4.2.2

Cells and culture conditions.
Human THP-1 monocytes, murine J774A.1 macrophages, human HL-60 cells,

COS-7 cells, RPMI-1640 medium with and without phenol red (containing 2 mM Lglutamine, 10 mM HEPES, 1 mM sodium pyruvate, 4500 mg/L glucose and 1500 mg/L
sodium bicarbonate), Dulbecco’s modified Eagle’s medium (DMEM) with and without
phenol red (containing 4 mM L-glutamine, 4500 mg/L glucose, 1 mM sodium pyruvate
and 1500 mg/L sodium bicarbonate), Opti-MEM medium, and gentamicin sulfate
solution (50 mg/mL) were purchased from the American Type Culture Collection
(ATCC) (Manassas, VA). Fetal bovine serum (FBS) and One-Shot TOP10 chemically
competent E. coli were purchased from Invitrogen (Grand Island, NY).
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THP-1 monocytes were passaged in RPMI-1640 containing 10% FBS and 50
µg/mL gentamicin (complete medium) (Wang et al. 2013); J774A.1 macrophages and
COS-7 cells were passaged in DMEM medium containing 10% FBS and 10 units/mL
penicillin and 10 µg/mL streptomycin (complete medium) (Wang et al. 2013); HL-60
cells were passaged in RPMI-1640 containing 10% FBS and penicillin and streptomycin.
All cells were cultured at 37°C in an atmosphere of 95% air/5% CO2. THP-1 cells and
HL-60 cells were differentiated into macrophage-like cells by adding PMA to the culture
medium (final concentration 100 nM) and growing the cells for 72 h.
4.2.3

Expression of human DAGLβ in COS7 cells.
A human DAGLβ expression plasmid was transformed into One-Shot Top10

chemically competent E. coli and the cloned plasmid was purified using QIAGEN
Plasmid Midi Kit following the manufacturer’s instructions. COS-7 cells were
transfected with either human DAGLβ cDNA or empty plasmid (control) using the
FuGene 6 Transfection Reagent in Opti-MEM medium and the transfected cells
incubated overnight. The transfection medium was removed and replaced with fresh
(complete) DMEM medium. After an additional 48 h incubation, the medium was
replaced again with (complete) DMEM medium supplemented with G418 (500 µg/mL)
and the cells were maintained in this medium for 3 weeks. The culture medium was
replaced every 3 days with fresh medium containing G418 to select for positive clones.
After 3 weeks, total RNA was isolated from the DAGLβ-transfected and mocktransfected cells, and the level of DAGLβ mRNA was determined by quantitative-real
time-PCR. In addition, the transformed cells were washed with PBS and harvested in 50
mM Tris-HCl (pH 7.4) buffer and sonicated with 3 short bursts on ice. The 1-steroyl-267

arachidonoylglycerol (SAG) hydrolysis activity of the cell lysates was determined (see
below).
4.2.4

Preparation of cell lysates.
THP-1 monocytes were collected by centrifugation (1000 x g for 5 min), washed

with cold phosphate-buffered saline (PBS), resuspended in ice-cold 50 mM Tris-HCl (pH
7.4) buffer, and lysed by sonication (three 15 s bursts on ice at 30% maximum power).
THP-1 macrophage and J774A.1 macrophage monolayers (~80-90% confluent) were
washed with cold PBS, scraped into ice-cold 50 mM Tris-HCl (pH 7.4) buffer, and
sonicated. COS-7 cells transfected with DAGLβ and control COS-7 cells were harvested
with Accutase (2 mL, 5 min). Fresh DMEM containing 10% FBS was added to stop the
Accutase reaction and the detached cells were pelleted at 1000 x g (5 min), washed 3
times with sterile PBS, resuspended in ice-cold 50 mM Tris-HCl (pH 7.4) buffer and
sonicated. Protein concentrations of the cell lysates were determined using the BCA
reagent according to the manufacturer’s instructions (Thermo-Fisher). Cell lysates were
used fresh or flash frozen and stored at -80°C prior to use.
4.2.5

2-Arachidonoylglycerol biosynthesis by THP-1 macrophages.
THP-1 macrophage lysates (0.5 mg/mL protein concentration) were treated with

CaCl2 (10 µM final concentration) in 200 μL of 50 mM Tris-HCl (pH 7.4) in the absence
or presence of 1 mM ethylene glycol tetraacetic acid (EGTA), 10 µM U73122, or 10 µM
Orlistat. Incubations went for 5 min at 37°C with shaking (550 rpm). The reactions were
quenched by the addition of 300 μL of ethyl acetate (containing 0.1% acetic acid) and
fortified with 2-AG-d8 (internal standard). After centrifugation of samples at 1500 x g (5
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min, 4°C), the organic layer was collected in a clean tube and dried under N2. Residues
were reconstituted in 100 μL methanol/water (1:1, v/v) and the levels of 2-AG quantified
by LC-MS/MS.
4.2.6

SAG hydrolysis assay.
Cell lysate was diluted to 0.3 mg/mL lysate in DAGL buffer (5 mM CaCl2, 100

mM NaCl, 50 mM HEPES buffer, pH 7.4) (final volume 70 µL). SAG (20 µM final
concentration) was added and the reaction duration was 30 min (37°C). Reactions were
stopped by adding ethyl acetate (containing 0.1% acetic acid) fortified with 2-AG-d8.
After drying the organic extracts, the residues were reconstituted in methanol:water (1:1,
v/v) for LC-MS/MS analysis.
4.2.7

2-AG biosynthesis of human DAGLβ-transfected COS7 cells.
To determine the endogenous level of 2-AG in DAGLβ-transfected COS7 cells as

compared to native COS-7 cells, we seeded the cells in two 6 well plates to grow to 80%
confluency followed by incubation with 3 µM ionomycin for 30 min at 37°C. The
culture medium was extracted with 2-AG-d8 adulterated ethyl acetate, and the organic
extract was dried under nitrogen and reconstituted in methanol:water (1:1, v/v) for LCMS/MS analysis. In a subsequent experiment, cells were pretreated with 10 µM orlistat,
a DAGLβ inhibitor, for 30 min, followed by treatment with 3 µM ionomycin for an
additional 30 min. The culture medium was extracted to quantify 2-AG levels and cell
lysates were used for the SAG hydrolysis assay.
To determine the role of NADPH oxidase in the DAGLβ-transfected COS-7 cells,
the cells were pretreated with a Nox inhibitor (10 µM VAS) for 30 min followed by an
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additional 30 min incubation with 10 µM AA to stimulate Nox activity (Mangum et al.
2015). The culture medium was extracted to quantify 2-AG levels and cell lysates were
used for the SAG hydrolysis assay.
4.2.8

Treatment of macrophages with either extracellular superoxide or Nox
activators

4.2.8.1

LDH cytotoxicity assay.
THP-1 monocytes (2 x 105 cells/well) were differentiated into macrophages

(PMA, 100 nM, 72 h) in a 96-well plate. The macrophages were treated with increasing
concentrations of xanthine (0-250 μM) and a fixed amount of xanthine oxidase (0.1
mU/mL) in 200 μL of PBS for 15 min at 37°C in an atmosphere of 95% air/5% CO2.
Cells were monitored for overt cytotoxicity by mixing 100 μL of the culture supernatant
with 2 volumes of LDH reagent solution, followed by incubation at 37°C for 30 min to
determine LDH activity (at 490 nm in a plate reader). Alternatively, cell lysates were
prepared in 50 mM Tris-HCl (pH 7.4) and the intracellular LDH activity was determined
(at 690 nm in a plate reader).
4.2.8.2

Quantitation of reactive oxygen species in macrophages.
J774A.1 macrophages or THP-1 macrophages in phenol red-free culture medium

(1 x 105 cells/well in a 96-well plate) were treated for 30 min with PMA (0.32 M) or
DMSO, followed by the addition of the oxyradical probe HE (20 µM final concentration).
Immediately after adding the HE, the fluorescence signal was monitored for 90 min in a
Molecular Devices SpectraMax M5 plate reader (ex: 485 nm; em: 590 nm). Fluorescence
was normalized against cell protein content to control for variations in cell number in
each well.
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The Nox activity of a THP-1 macrophage lysate was determined by incubating
lysate protein (0.3-0.5 mg/ml) with lucigenin (5 μM final concentration) and NADPH
(100 μM final concentration) in 50 mM Tris-HCl (pH 7.4) buffer containing 1 mM
EGTA. The resulting luminescence was monitored for 15 min in a Molecular Devices
SpectraMax M5 plate reader. Generation of superoxide by a xanthine oxidase system
was also determined using the lucigenin probe.
The superoxide-specific product 2-OH-Et+ (Zielonka et al. 2009) was quantified
by LC-MS/MS, as previously reported (Mangum et al. 2015). Briefly, cells were treated
with either PMA (3.2 µM) or oxLDL (50 µg/mL) in phenol red- and FBS-free culture
medium for 30 min at 37C, followed by the addition of the HE probe (20 µM final
concentration). After a 20 min incubation with the HE probe, the cells were harvested
and washed with PBS. The cells were then sonicated in 300 µL methanol:water (1:1, v/v)
and the lysates were centrifuged (16,100 x g for 5 min). The supernatant following
centrifugation was loaded into LC vials and analyzed by LC-MS/MS (Mangum et al.
2015).
4.2.8.3

Determination of 2-AG levels in macrophages.
THP-1 macrophages (in 60-mm dishes) were pretreated with 1 μM paraoxon (PO)

in serum-free medium for 30 min, to prevent 2-AG degradation by hydrolytic enzymes,
followed by either a 10-min incubation with 150-μM xanthine–0.1-mU/mL xanthine
oxidase or a 24-h incubation with acLDL (20 µg/mL). The culture medium was
harvested, fortified with 2-AG-d8, and extracted with 2 volumes ethyl acetate containing
0.1% acetic acid. The organic layer was collected and dried under N2, and samples were
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reconstituted with 100 μL methanol:water (1:1, v/v). Extracts were analyzed by LCMS/MS to quantify 2-AG levels.
J774A.1 macrophages were treated with increasing concentrations of PMA (0,
0.32, 3.2, or 32 µM) in 1-mL PBS. After a 10 min incubation, the culture medium was
fortified with 2-AG-d8 and extracted with ethyl acetate to quantify the levels of 2-AG.
Due to the short incubations (10 min) and because 2-AG is degraded less rapidly in
J774A.1 cells relative to THP-1 cells (Xie et al. 2010), the J774A.1 cells were not
pretreated with a serine hydrolase inhibitor prior to adding PMA. To determine whether
Nox has a role in 2-AG biosynthesis, macrophages were pretreated with a Nox inhibitor
(10 µM apocynin) prior to adding stimulants (PMA or AA).
4.2.8.4

Role of cannabinoid receptors in MD-derived superoxide levels in
macrophages.

Macrophages (J774A.1 or THP-1) were overlaid with FBS-free and phenol red-free
culture medium containing either the CB1 receptor antagonist rimonabant (1 μM) or the
CB2 receptor antagonist AM630 (1 μM) for 30 min, followed by addition of the nonspecific cannabinoid receptor agonist WIN 55,212-2 (10 or 25 μM, 24 h incubation).
After removal of the agonists and antagonists, the cells were challenged with the redox
cycling agent MD (40 μM) for 30 min. The culture medium was removed and fresh
medium containing the oxyradical probe HE (10 μM) was added. After 20 min
incubation with the probe, the macrophages were washed and harvested in 300 μL of 1:1
methanol:water, sonicated, and the lysate centrifuged (16,100 x g, 10 min, 4°C). The
supernatant was collected for LC-MS/MS analysis of 2-OH-Et+ (Mangum et al. 2015).
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In a separate experiment, the macrophages were pretreated with the selective
cannabinoid receptor antagonists for 30 min, followed by a 4-h incubation with WIN
55,212-2. MD (40 μM final concentration) was added directly to the culture medium
containing the agonists and antagonists (i.e., compounds were not removed before adding
MD), and the incubation proceeded for an additional 30 min. The culture medium was
removed and fresh medium containing the oxyradical probe HE (10 μM) was added.
After 20 min, the macrophages were washed and harvested in 300 µL methanol/water
(1:1, v/v), sonicated, centrifuged, and the supernatant collected.
4.2.8.5

LC-MS/MS analysis.
2-AG analysis was performed on a UPLC-MS/MS system (Waters Acquity UPLC

interfaced with a Thermo Quantum Access Max triple quadrupole mass spectrometer)
using the method described by Wang et al. (2013). Extracts were injected (10 μL) onto
an Acquity UPLC BEH C18 column (2.1 mm × 100 mm, 1.7 μm) equipped with a
VanGuard precolumn (2.1 mm × 5 mm, 1.7 μm). For 2-AG and 2-AG-d8, the mobile
phases were a blend of solvent A (2 mM ammonium acetate and 0.1% acetic acid in
water) and solvent B (2 mM ammonium acetate and 0.1% acetic acid in methanol). The
elution program was described previously (Wang et al. 2013) and the flow rate was 0.4
mL/min. The column eluate was directed into the mass spectrometer using heated
electrospray ionization in the positive ion mode. Single-reaction monitoring (SRM) of
analytes were: 2-AG, [M+NH4]+ m/z 396 > 287; 2-AG-d8, [M+NH4]+ m/z 404 > 294.
Scan times were 0.2 s per SRM and the scan width was m/z 0.01. The internal standard
2-AG-d8 was used for quantification.
73

4.2.8.6

Statistical analyses.
Data are expressed as means ± SD. Statistical significance between two groups

was determined by Student’s t-test. Statistical significance between more than two
groups of data were compared by one-way ANOVA (Student-Newman-Keuls method).
Values of p < 0.05 were considered to be significant.
4.3
4.3.1

Results
Treatment of human macrophage-like cells with oxLDL enhances
superoxide levels
It was previously reported that modified LDLs stimulated Nox activity (and

elevated intracellular ROS) in macrophages in a CD36-dependent manner (Shen 2010;
Shen 2012; Noda et al. 2015). Consistent with this, we found that mRNA levels for the
catalytic subunit and cytosolic regulatory protein of Nox (Nox2 and p47phox, respectively)
were induced in human HL-60 cells by either PMA or all-trans-retinoic acid (Figure
4.1A). The rationale for using differentiated HL-60 cells was that these cells express
CD36 (Greenberg et al. 2006) and Nox2 (Brechard et al. 2009). Nox activity in the
PMA-primed cells was stimulated by exogenous arachidonic acid, as assessed by the rate
of oxidation of the oxyradical probe HE (Figure 4.1B). Moreover, superoxide levels
[assessed by measuring the superoxide-specific oxidation product 2-hydroxyethidium (2OH-Et+) by LC-MS/MS] in HL-60 macrophages treated with oxLDL were significantly
higher than those in untreated controls (Figure 4.1C). These data are consistent with the
notion that oxLDL can stimulate Nox activity (and increase superoxide levels) in
macrophages (Shen 2010; Shen 2012; Noda et al. 2015).
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4.3.2

Human THP-1 and murine J774 cells biosynthesize 2-arachidonoylglycerol
Macrophages exposed to oxLDL are also known to make the endocannabinoid 2-

AG (Jiang et al. 2009; Xie et al. 2010); however, the mechanistic details for this response
have not been clarified. Phospholipase C β (PLCβ) and diacylglycerol lipase β (DAGLβ)
are calcium-dependent enzymes that have important roles in signal transduction pathways
and are involved in the biosynthesis of 2-AG. PLCβ cleaves phosphatidylinositol 4,5bisphosphate lipids releasing diacylglycerol (DAG), then DAGLβ specifically hydrolyzes
the DAG 1-acyl-2-arachiondoylglycerol at the sn-1 position to provide 2-AG. To
understand the connection between oxLDL-derived ROS and 2-AG biosynthesis, we next
examined whether 2-AG biosynthesis is increased in human and murine macrophage
models under various states of oxidative stress. Human THP-1 cells and murine J774A.1
cells were used because they are widely used models of macrophage biology.
First, we verified that macrophage lysate (THP-1) could be activated by calcium
ions to yield 2-AG (Figure 4.2). Addition of PLCβ and DAGLβ inhibitors (U73122 and
Orlistat, respectively) blocked the effect of calcium on 2-AG production. Furthermore,
addition of the calcium chelator EGTA also prevented 2-AG synthesis. Second,
incubation of SAG, a DAGL substrate, with macrophage lysate (J774A.1) resulted in a
marked increase in 2-AG (~14-fold; Figure 4.3). Together, these data are consistent with
literature indicating that elevated calcium levels are vital for the production of 2-AG
(Okada et al. 2011; Signorello et al. 2011; Shonesy et al. 2015; Szekeres et al. 2015). It
also demonstrates that THP-1 and J774A.1 cells have the biochemical machinery to
produce 2-AG.
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4.3.3

Macrophages challenged by extracellular superoxide flux
Intact THP-1 macrophages were subjected to oxyradical stress by treatment with

an extracellular superoxide generating system (xanthine oxidase; 15 min) (Figure 4.4).
Superoxide production by the xanthine oxidase system was verified by the detection of
the lucigenin-derived product (Figure 4.4) and the HE-derived 2-OH-Et+ product (Figure
4.4), a specific product formed by the reaction of the HE probe with superoxide (Zielonka
et al. 2009). To assess the xanthine oxidase-derived superoxide flux, a cell-free
incubation of xanthine oxidase system with cytochrome c for 3 min enabled the flux to be
determined (271±2 pmol/min or 1.36±0.01 µM/min). The xanthine oxidase-derived
superoxide flux was not overtly cytotoxic to THP-1 cells (Figure 4.5). Moreover, intact
THP-1 macrophages treated with the xanthine oxidase system produced increased
amounts of 2-AG (2.3-fold) compared with the untreated cells (Figure 4.6). Elevated 2AG levels were also observed in another cell line (COS-7 cells) treated with the xanthine
oxidase system (data not shown).
4.3.4

Activation of macrophage NADPH oxidase is associated with increases in
2-AG levels
We verified that treatment of either J774A.1 macrophages or THP-1 macrophages

with PMA (a Nox activator) in the presence of the oxyradical probe HE caused
significant increases in the rate of HE oxidation relative to the vehicle-treated cells
(Figure 4.7A,B). Furthermore, PMA caused a concentration-dependent increase in 2-AG
levels in J774A.1 macrophages (Figure 4.7C). Importantly, the PMA-induced 2-AG
production was abrogated by the Nox inhibitor apocynin (Figure 4.7D). Similar findings
were observed in PMA-primed HL-60 cells treated acutely with PMA (3.2 µM; Figure
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4.8, Figure 4.9). These data taken together suggest that 2-AG biosynthesis is correlated
with increased Nox activity and oxyradical stress.
Because modified LDLs can stimulate Nox activity in a CD36-dependent manner
(Shen 2010; Shen 2012; Noda et al. 2015), THP-1 macrophages were treated with acLDL
(which has high affinity for CD36) in the presence or absence of 1 M paraoxon, which
stabilizes 2-AG by inhibiting carboxylesterase 1-mediated degradation of 2-AG in this
cell line (Xie et al. 2010). Exposure of cells to acLDL resulted in increased 2-AG levels
compared with control cells (Figure 4.10A). AcLDL alone caused a significant increase
in 2-AG levels, while the combination of acLDL and paraoxon led to a slightly greater
increase than that of acLDL alone. Furthermore, when murine and human cells (J774A.1
and THP-1 macrophages) were stimulated with the Nox activator arachidonic acid,
significantly more 2-AG was produced as compared with DMSO- treated cells (Figure
4.10B). This effect was attenuated in THP-1 cells by a DAGLβ inhibitor (Figure 4.10B).
The magnitude of the 2-AG levels was greater in the murine cell line compared with the
human cell line, which might reflect the differences in Nox2 expression in mice and
human macrophages (Gaines et al. 2005).
Superoxide rapidly dismutates to H2O2, which is a second messenger in signal
transduction pathways (Griendling 2013; Ross et al. 2014). The addition of H2O2 to
either intact living THP-1 macrophages or THP-1 cell lysates increased the levels of 2AG when compared to vehicle controls (Figure 4.11A,B). This suggested that
superoxide/H2O2 could stimulate DAGL activity. However, when recombinant DAGL
was pre-treated with H2O2 its activity toward SAG was unchanged (Figure 4.12),
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indicating that any effects of H2O2 on DAGL are probably indirect and not due to
chemical modification of a cysteine residue that regulates enzyme activity.
4.3.5

Menadione-derived superoxide levels are attenuated by the cannabinoid
receptor agonist WIN 55,212-2
Addition of the redox cycling agent MD (40 µM) to J774A.1 macrophages

resulted in a significant increase in superoxide levels, as measured by 2-OH-Et+ (Figure
4.13A,B). A non-selective cannabinoid receptor agonist, WIN 55,212-2, significantly
attenuated the levels of MD-derived superoxide (Figure 4.13B). Similar effects of WIN
55,212-2 on superoxide levels were observed in THP-1 macrophages (Figure 4.14A).
WIN 55,212-2 did not stimulate superoxide production in cells on its own (data not
shown). In addition, the CB1 and CB2 receptor antagonists, rimonabant and AM630,
respectively, both appeared to abrogate the anti-oxidative effects of WIN 55, 212-2 in
J774A.1 macrophages (Figure 4.14B).
4.3.6

DAGLβ-dependent 2-AG biosynthesis following Nox activation by
arachidonic acid
Stable overexpression of human DAGL expression in COS-7 cells was verified

by measuring the DAGL mRNA level and SAG hydrolysis activity (Figure 4.15A); both
parameters were significantly elevated in the DAGLβ-transfected cells compared to
mock-transfected cells. Further, COS-7 cells overexpressing DAGLβ produced more 2AG than native COS-7 cells when stimulated with ionomycin (Figure 4.15B).
Pretreatment of cells with the DAGLβ inhibitor orlistat abrogated the response to
ionomycin. Stimulation of DAGLβ-overexpressing cells with exogenous AA resulted in
a marked increase in 2-AG levels compared to control (untreated DAGLβ-overexpressing
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cells) (Figure 4.15C). This effect was attenuated by either a Nox inhibitor or DAGLβ
inhibitor (Figure 4.15C). Similar effects on 2-AG levels were obtained using THP-1 cells
treated with AA in the absence or presence of a Nox inhibitor (Figure 4.10B).
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Figure 4.1

mRNA of NADPH oxidase (Nox) components and Nox-derived reactive
oxygen species are induced in HL-60 macrophages by various stimulants.

(A) Human HL-60 cells treated with either PMA or all-trans-retinoic acid (ATRA) have
increased levels of DAGL, p47phox, and Nox2 mRNA compared to vehicle (DMSO)treated cells. (B) PMA-primed HL-60 cells were treated with the indicated
concentrations of arachidonic acid (AA), followed by the addition of HE (20 µM) and the
rate of HE oxidation was monitored by fluorescence for 60 min. (C) Human HL-60 cells
were differentiated into macrophages by PMA (100 nM, 72 h), then treated with oxLDL
(50 µg/mL) for 24 h. The levels of superoxide in the cells was determined by adding the
oxyradical probe HE for 20 min. After removal of the medium, the cells were extracted
in methanol/water (1:1, v/v) (300 µL) and the relative amount of 2-OH-Et+ (surrogate
measure of superoxide) was quantified by LC-MS/MS by measuring the area under the
chromatographic peak. Data represents mean ± SD n=3. * p<0.05, Student’s t-test when
two groups are compared, one-way ANOVA (Student-Newman-Keuls method) when
more than two groups are compared.
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Figure 4.2

THP-1 and J774A.1 macrophages have the biochemical machinery to
produce 2-AG.

THP-1 macrophage lysates make 2-AG when stimulated with Ca2+. Calcium activates
both PLC-β and DAGLβ activities, which can be blocked with the chelator EGTA (left).
U73122 and Orlistat inhibit PLC-β and DAGLβ, respectively. In the presence of one or
both of these inhibitors, 2-AG biosynthesis by the THP-1 macrophage lysate was
blocked. Mass chromatogram (right) for 2-AG + 1(3)-AG indicated that the isomers of
arachidonoylglycerol elute as one peak and that 2-AG biosynthesis was blocked by a
DAGL inhibitor. Rearrangement of 2-AG to 1(3)-AG due to acyl migration is a wellcharacterized phenomenon (Shen 2010; Shen 2012; Noda et al. 2015). Data represents
mean ± SD n=3.* p<0.05, Student’s t-test.
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Figure 4.3

J774A.1 macrophages catalyze the formation of 2-AG.

J774A.1 macrophages catalyze the formation of 2-AG from the DAGL substrate 1stearoyl-2-arachidonoylglycerol (SAG). Cell lysate (0.3 mg/ml) was incubated with
exogenous SAG (20 µM) for 30 min. The reaction was quenched with one volume of 2:1
(v/v) chloroform/methanol doped with 2-AG-d8, and the organic layer was collected and
dried under nitrogen. The residue was re-suspended in methanol/water (1:1, v/v) to
quantify 2-AG levels by LC-MS/MS. N.E., represents the non-enzymatic reaction. Data
represents mean ± SD n=3.* p<0.05, Student’s t-test.

Figure 4.4

THP-1 macrophages treated with extracellular superoxide via a xanthine
oxidase system enhanced the amount of 2-AG made by the cells.

The xanthine oxidase system liberates superoxide, which reacts with lucigenin to form
the chemiluminescent product N-methylacridone*. The area-under-curve is a measure of
the amount of superoxide produced. LC-MS/MS analysis confirmed that the superoxidespecific oxidation product 2-OH-Et+ was produced when the oxyradical probe HE was
added to the xanthine oxidase system (data not shown).
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Figure 4.5

Xanthine oxidase system is not cytotoxic to THP-1.

Xanthine oxidase (XO)-derived superoxide was not cytotoxic to THP-1 macrophages
following a 15 min incubation and can be used as a model of paracrine superoxide
signaling (i.e., superoxide derived from the extracellular space). 0.1% Triton X100 was
used as positive control for cell death. Data represents mean ± SD n=3. * p<0.05,
Student’s t-test.
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Figure 4.6

THP-1 macrophages treated with extracellular superoxide via a xanthine
oxidase system enhanced the amount of 2-AG made by the cells.

Treatment of THP-1 macrophages with the extracellular xanthine oxidase system
heighted the production of 2-arachidonoylglycerol compared to the negative control.
Data represents mean ± SD. * p<0.05, Student’s t-test.
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Figure 4.7

PMA-activated macrophages produce elevated amounts of superoxide and
2-AG.

Murine J774A.1 macrophages (A) and human THP-1 macrophages (B) were treated with
either DMSO (PMA ) or 0.32 µM PMA (PMA +) for 30 min, then loaded with the
oxyradical probe HE (20 µM). The resulting fluorescence was monitored for 90 min at
37°C. PMA-treated murine J774A.1 macrophages and human THP-1 macrophages
exhibited a 65% and 13% increase in HE oxidation rates, respectfully, compared to
vehicle-treated control. RFU, relative fluorescence units. (C) Murine J774A.1
macrophages treated with the indicated amount of PMA for 10 min exhibited a
concentration-dependent increase in 2-AG production, suggesting that 2-AG biosynthesis
is correlated with increased oxidative stress. (D) Pre-treatment of J774A.1 macrophages
with the Nox inhibitor apocynin abrogated the PMA-stimulated production of 2-AG.
Data represents mean ± SD n=3. * p<0.05, Student’s t-test when two groups are
compared, one-way ANOVA (Student-Newman-Keuls method) when more than two
groups are compared.
85

Figure 4.8

PMA-activated macrophages produce elevated amounts of superoxide and
2-AG.

(A) HL-60 cells were differentiated into macrophages (PMA, 100 nM, 72 h), then treated
with either PMA (3.2 µM) or DMSO followed by the addition of HE (20 µM final
concentration). The rate of HE oxidation was monitored in a fluorescent plate reader for
120 min. (B) Quantitative analysis of the data shown in (A) is provided as a bar graph.
Data represents mean ± SD n=3. * p<0.05, Student’s t-test.
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Figure 4.9

Macrophages challenged with acetylated low-density lipoprotein,
arachidonic acid, and H2O2 produced elevated amounts of 2-AG.

(A) The superoxide-specific product 2-OH-Et+ was determined in HL-60 macrophages
that had been treated with DMSO, PMA (3.2 µM), or PMA (3.2 µM) and VAS (a Nox
inhibitor, 10 µM) for 30 min. After 30 min, the culture medium was removed and the
cells overlaid with fresh medium containing 20 µM HE, followed by an additional
incubation period of 20 min. (B) 2-AG levels were determined in HL-60 macrophages
treated with either DMSO or PMA (3.2 µM). Data represents mean ± SD n=3. *
p<0.05, Student’s t-test when two groups are compared, one-way ANOVA (StudentNewman-Keuls method) when more than two groups are compared.
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Figure 4.10

Macrophages challenged with acetylated low-density lipoprotein,
arachidonic acid, and H2O2 produced elevated amounts of 2-AG.

(A) THP-1 macrophages challenged with 20 µg/mL acLDL for 24 h exhibited an increase
in 2-AG levels. Challenge with a combination of acLDL and PO also enhanced 2-AG
levels, but they were not significantly different from acLDL treatment alone. (B)
Exogenous arachidonic acid (AA) stimulated DAGLβ-dependent biosynthesis of 2-AG
by macrophages, which was inhibited by orlistat. Data represents mean ± SD n=3. *
p<0.05, Student’s t-test when two groups are compared, one-way ANOVA (StudentNewman-Keuls method) when more than two groups are compared.
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Figure 4.11

Macrophages challenged with acetylated low-density lipoprotein,
arachidonic acid, and H2O2 produced elevated amounts of 2-AG.

(A) Intact living THP-1 cells were treated with 1-mM H2O2 for 60 min, followed by 2AG analysis. (B) THP-1 cell lysates were treated with 1-mM H2O2 for 60 min, followed
by 2-AG analysis. Cell lysate was also treated with Ca2+ to stimulate 2-AG synthesis (as
a positive control). The vehicle (Veh) for H2O2 was water. Data represents mean ± SD
n=3. * p<0.05, Student’s t-test when two groups are compared, one-way ANOVA
(Student-Newman-Keuls method) when more than two groups are compared.
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Figure 4.12

Relative 2-AG amounts in macrophages challenged H2O2.

Human DAGLβ overexpressed cell lysates were treated with 1-mM H2O2 for 90 min,
followed by 2-AG analysis. The vehicle (Veh) for H2O2 was water . Data represents
mean ± SD n=3. * p<0.05 (relative to control or vehicle), Student’s t-test.
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Figure 4.13

Pretreatment of J774A.1 macrophages with the non-selective CB agonist
WIN 55,212-2 attenuated 2-OH-Et+ levels following treatment with
menadione (MD).

(A) MD is redox cycling agent that produces superoxide in cells. Addition of MD (40
µM) to J774A.1 macrophages for 30 min markedly increased superoxide (2-OH-Et+)
levels relative to vehicle. (B) WIN 55,212-2 (WIN) attenuated the levels of the MDderived superoxide (2-OH-Et+). # p<0.05 relative to vehicle (Veh) control; Data
represents mean ± SD n=4-9. ** p<0.01 relative to MD only-treated cells; * p<0.05
relative to MD/WIN–treated cells, one-way ANOVA (Student-Newman-Keuls method).
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Figure 4.14

Pretreatment of J774A.1 macrophages with the non-selective CB agonist
WIN 55,212-2 attenuated 2-OH-Et+ levels following treatment with
menadione (MD).

(A) Addition of MD (40 µM) to THP-1 macrophages for 30 min markedly increased
superoxide (2-OH-Et+) levels relative to vehicle. WIN 55,212-2 (WIN, 10 µM)
attenuated the levels of MD-derived superoxide (2-OH-Et+). (B) The effect of WIN
(25µM) on the levels of MD-derived superoxide (2-OH-Et+) was abrogated by CB1 and
CB2 receptor antagonists [rimonabant (Rimo) and AM630, respectively]. # p<0.05
relative to vehicle (Veh) control; Data represents mean ± SD n=4-9. ** p<0.01 relative
to MD only-treated cells; * p<0.05 relative to MD/WIN–treated cells, one-way ANOVA
(Student-Newman-Keuls method).
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Figure 4.15

COS-7 cells that stably overexpress human DAGL produce more 2-AG
than control COS-7 cells, and inhibition of Nox activity attenuated 2-AG
levels.

(A) Expression of human DAGL was verified by measuring its mRNA level in COS-7
cells (left) and the SAG hydrolysis activity of cell lysates (right). (B) 2-AG levels were
determined in DAGL-COS-7 cells and control COS-7 cells following stimulation with
ionomycin in the presence and absence of the DAGL inhibitor orlistat. (C) 2-AG levels
were determined in DAGL-COS-7 cells following stimulation with arachidonic acid in
the presence and absence of a Nox inhibitor (VAS) or DAGL inhibitor (orlistat). Data
represents mean ± SD n=3. * p<0.05, Student’s t-test when two groups are compared,
one-way ANOVA (Student-Newman-Keuls method) when more than two groups are
compared.

93

Figure 4.16

Scheme describing how modified LDLs can activate signaling pathways
that stimulate 2-AG biosynthesis via Nox activation.
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4.4

Discussion
Macrophages have important roles in lipid metabolism and immunity. In this

study, we have extended our previous work on Nox in monocytes/macrophages (Mangum
et al. 2015) to examine whether stimulation of this enzyme complex modulates the
endocannabinoid system by activating the 2-AG biosynthetic enzyme DAGL. Nox is
the only oxidoreductase that produces superoxide as its primary end product; however,
whether Nox (and the reactive oxygen species it produces) interfaces with the bioactive
endocannabinoids has not been studied. Thus, we wondered whether overactive redox
pathways in immune cells would stimulate downstream compensatory pathways,
including increased 2-AG biosynthesis, to reestablish homeostasis. In this study it was
demonstrated that 2-AG levels in human THP-1 cells and murine J774A.1 cells, which
are two widely used macrophage-like cell lines, were elevated following exposures to
either extracellular oxyradicals (via xanthine oxidase system) or intracellular oxyradicals
derived from the activated Nox complex. These results suggested that oxyradical stress
in the macrophages was causally related to enhanced biosynthesis of 2-AG. In support of
this notion, the effects of these stressors on 2-AG biosynthetic activity were blunted by
the addition of Nox and DAGL inhibitors (Mangum et al. 2015).
Current therapies for cardiovascular disease mainly target well-established risk
factors such as high blood pressure and elevated cholesterol levels. However, the
endocannabinoid system and oxidoreductases that generate ROS are emerging as
attractive targets for reducing inflammation and oxidative stress in the cardiovascular
wall. Our data suggest that increased rates of superoxide production, induced by either
PMA, arachidonic acid, or a xanthine oxidase system, correlated with increased rates of
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2-AG biosynthesis. PMA is a potent activator of protein kinase C (PKC) and the small
G-protein Rac; the activated proteins work in concert to stimulate the biosynthesis of
Nox-derived superoxide (Schroder et al. 2007; Serrander et al. 2007). Xanthine oxidase,
on the other hand, is an oxidoreductase that generates superoxide anion via the oxidation
of either hypoxanthine to xanthine or xanthine to uric acid. The increased rates of 2-AG
biosynthesis resulting from the elevated superoxide levels might be a compensatory
mechanism invoked by oxidative stress. The endocannabinoids have well known
homeostatic regulatory functions that help to dampen the effects of noxious stimuli.
Consistent with this notion, we showed that the non-selective cannabinoid receptor
agonist WIN 55,212-2 attenuated the MD-derived superoxide levels in macrophages.
Furthermore, either the selective CB1 or selective CB2 receptor antagonists could
abrogate the beneficial effect of WIN 55,212-2 (Figure 4.14B). These data indicate that
the endocannabinoid system, including the CB1 and CB2 receptors and their ligands,
might be an important therapeutic target to modulate oxidative stress. The specific
signaling pathways evoked by CB1 and CB2 receptor activation are undefined in our
study; however, CB1- and CB2-dependent signaling is known to modulate p38 and
ERK1/2 stress kinase activity (Pacher and Steffens 2009), which might account in part
for the WIN 55,212-2-dependent decrease in superoxide levels seen here. More work,
however, is needed to characterize the integration of signals emanating from the two
cannabinoid receptors and how they balance each other to regulate the intracellular redox
state.
Our results also showed that increased levels of 2-AG could be produced in
macrophages exposed to acLDL (Figure 4.10A). The unregulated phagocytosis of
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modified LDLs by macrophages causes foam cell formation; however, blockade of the
CB1 receptor or activation of the CB2 receptor was shown to reduce foam cell formation
(Sugamura et al. 2010) and atherosclerosis development (Booz 2011). In addition, when
ApoE-/- mice were treated with WIN 55,212-2, the number of macrophages in plaque
lesions was decreased as was the expression of TNF-α, IL-6, and MCP-1 in the plaques
(Wang et al. 2010). The beneficial effects of WIN 55,212-2 were blocked with a CB2
antagonist. It is known that modified LDL can activate Nox activity and increase ROS in
macrophages in a CD36-dependent manner (Park et al. 2009). Thus, a compensatory
response to Nox activation under these conditions might involve an increase in 2-AG
levels to help dampen oxidative stress via CB2 signaling.
The relationship between oxidative stress and endocannabinoids is complex and
still poorly understood. However, Rajesh et al. (Rajesh et al. 2010) demonstrated that
Nox-derived superoxide levels in cultured human coronary artery endothelial cells were
attenuated by a synthetic CB2-selective agonist. This effect is consistent with the known
beneficial properties of CB2 agonists. For instance, treatment of endothelial cells and
smooth muscle cells with a synthetic CB2 agonist attenuated TNF- production and
evoked other anti-inflammatory responses (Rajesh et al. 2010). On the other hand, CB1
receptor activation induced the production of pro-inflammatory mediators and substantial
oxidative stress (Pacher and Steffens 2009). Because the endocannabinoids bind to CB1
and CB2 receptors with roughly equal affinity, an increased endocannabinoid
concentration in the vessel wall might elicit both pro- and anti-inflammatory and
oxidative effects depending on the relative strength of the signal transduction pathways
evoked by CB1 and CB2 receptor signaling. Although there is conflicting literature
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concerning the role of endocannabinoids in the pathogenesis of atherogenesis (Mackie
2010), it is generally accepted that an imbalance in the endocannabinoid system and the
overproduction of Nox-derived superoxide and H2O2 disrupts redox circuits and induces
inflammatory mediators (Pacher 2007; Drummond et al. 2011).
In conclusion, this study provides insight into how Nox signals interface with the
activation of the rate-limiting enzyme of 2-AG biosynthesis, DAGLβ. We demonstrated
that heightened oxyradical flux via either extracellular (paracrine)- or intracellular (Nox)derived superoxide leads to increased biosynthesis of 2-AG, thereby enhancing the
macrophage "endocannabinoid tone”. It is suggested that this is part of a compensatory
mechanism to counteract inflammation and oxidative stress, most likely via CB-receptor
dependent signaling mechanism and downstream signaling cascades in inflammatory
cells (Figure 4.16) (Park et al. 2009).
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CHAPTER V
SERINE HYDROLASE PROFILING OF VASCULAR SMOOTH MUSCLE CELLS
5.1

Introduction
Atherosclerosis is a spatially nonrandom, nonlinear process that occurs at

branching points in the arterial tree that are prone to lesion formation due to disrupted
blood flow (Tabas et al. 2015). The pathophysiology of atherosclerosis as it pertains to
phagocytic cells and endothelial cells is well characterized. This chapter focuses on the
role that smooth muscle cells (SMCs) play in the cardiovascular disease (CVD) process.
It has been discussed in several reports that macrophages are critical in
atherogenesis; however, Tabas et al (2015) suggested that the expression of macrophage
derived proteins that are thought to be pro-inflammatory markers of atherosclerosis were
actually produced by smooth muscle cells (SMC). The atherosclerotic lesion in its
complexity consists of phagocytic cells such as macrophages, endothelial cells, lipids
such as oxidized (ox)LDL, and other cellular debris (Hopkins 2013). For example, SMCs
produce massive extracellular matrix proteins that contribute to lesion formation and
stability; however, the degradation of this “fibrous cap” leads to myocardial infarctions.
The differentiation of SMCs is incompletely understood, but it is clear that they
can acquire a broad spectrum of different phenotypes in response to physiological or
pathological stimuli. It is speculated that mechanical forces are important in the
recruitment and differentiation of SMCs during arterialization. Markers for SMCs
109

include four actin isoforms nonmuscle β-actin, nonmuscle γ-actin, smooth muscle γ-actin,
and most important is the smooth muscle α-actin in addition to nonmuscle-type myosin
heavy chain (MHC) type A (NMHC-A) and NMHC-B, which are both expressed in
human atherosclerotic lesions (Owens and Thompson 1986; Kuro-o et al. 1991; Monical
et al. 1993). Smooth muscle α-actin comprises 40% of the total cell protein and 70% of
total actin in the cells. Smooth muscle α-actin is transiently expressed in various stages
of differentiation and in myofibroblasts during wound healing (Owens and Thompson
1986; Owens 1995), and is the first identified marker for SMC differentiation during
vasculogenesis. Factors involved in the phenotypic modulation of SMCs include
mechanical factors and hemodynamic forces, such as shear stress and tangential wall
stress, and involve the reorientation of cells, increased protein and DNA synthesis, and
increased production of extracellular matrix (ECM) components such as collagens,
elastins, laminin, fibronectin, and glycosaminoglycans (Frink 2002). Decreased smooth
muscle α-actin expression is a consequence of increased fibronectin levels, which induces
cell migration, proliferation, and differentiation.
The atherosclerotic lesion is an asymmetrical thickening in the vessel wall
consisting of two main SMC proteoglycans—chondroitin sulfate proteoglycan (CSPG)
and dermatan sulfate proteoglycan (DSPG)—in addition to other ECM proteins and
SMCs (Frink 2002). The ECM has profound effects on cell behavior and plays a role in
atherogenesis. CSPG, for example, is an active scaffold that is vital in the regulation of
transport of plasma constituents and arterial permeability leading to the chemical change
in proteoglycans that lead to altered metabolic and biochemical functions (Wight 1989).
For example, oxidized low density lipoproteins (oxLDLs) enters the arterial wall from the
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circulating blood stimulating increased amounts of proteoglycans synthesis, which
enhances lipid accumulation in the intima. The accelerated rate of lipid entrapment leads
to changes in SMC phenotype. Previous reports suggest that the phenotypic change in
SMCs is not a consequence of the dyslipidemia but a pathological component of the
disease (Frink 2002; Tabas et al. 2015). The fibrous lesion is a network of ECM and
SMCs with increased intracellular pressure within the vessel wall. SMCs can take on a
macrophage-like phenotype in which they exhibit scavenger receptors on their surface
and have increased Golgi and rough endoplasmic reticulum structures (Owens 1996;
Frink 2002). Although SMCs are not as efficient as macrophages, they can phagocytose
modified LDL and metabolize cholesterol, although they do not efficiently esterify
intracellular free cholesterol. SMCs do not proliferate as macrophage foam cells, but
fusion with adjacent cells allows for even greater lipid accumulation. The inability to
effectively metabolize oxidized lipids results in apoptosis and the formation of a lipid
necrotic core (Frink 2002; Back et al. 2015). Additionally, the levels of proteins
characteristic of differentiated SMCs, including smooth muscle α-actin, smooth muscle
MHC, caldesom, vinculin, and desmin, are reduced. These changes are, at least in part,
reversible; however, failure to regulate the differentiated phenotype of vascular SMCs is
a contributing factor in the development and progression of atherosclerotic lesions.
Tabas et al (2012) suggest a balance of inflammatory and homeostatic responses that
regulate the overall atherogenic effects within lesional macrophage-like SMC.
Furthermore, plaque rupture is due to matrix metalloproteinases secretion, which
contributes to fibrous cap thinning (Libby et al. 2014).
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Because it has been reported that the endocannabinoids play a role in reducing
oxidative stress, and to date the serine hydrolase profile has yet to be determined in SMC,
we aim to identify which serine hydrolases are present in the human SMCs and the role
these hydrolytic enzymes play in the catabolism of 2-AG. It is well documented that 2AG and anandamide (AEA) are hydrolyzed by MAGL and FAAH, respectively (Carr et
al. 2013; Turcotte et al. 2015). Because SMCs participate in the inflammation that
contributes to atherosclerosis, it is important to inventory the serine hydrolases found
within this cell type. Our lab previously utilized the activity-based protein profiling
(ABPP)-multidimensional protein identification technology (MudPIT) to identify
uncharacterized serine hydrolases found in human macrophages (Wang et al. 2013).
Therefore, this chapter explores a similar objective to obtain a global view of the
hydrolases that are present in SMCs using the same analytical methods. Our approach
employs the use of an activity-based protein profiling (ABPP) probe, e.g. fluorophosphonate-biotin (FP-biotin), that covalently modifies the catalytic serine residue of
serine hydrolases, which can be enriched, proteolytically digested, and identified by LCMS/MS and MudPIT technology (Xie et al. 2010; Wang et al. 2013). ABPP enables the
activities of enzymes with conserved catalytic mechanisms, such as the serine hydrolase,
to be evaluated in their native environments in tissues and cells. ABPP-MudPIT has the
ability to distinguish between a wide ranges of target proteins with high specificity.
Although macrophages are elite producers of bioactive lipid mediators such as 2-AG,
other cell types, such as SMC, may have roles in the catabolism of this endocannabinoid.
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Figure 5.1

Pathophysiology of lipid laden foam cells.

(A) Under basal conditions, the vasculature has the biochemical machinery to metabolize
the level of interstitial fluids and other insults that present to disrupt blood flow such as
shear stress and LDLs. (B) In the event endothelial dysfunction, toxins or LDL
translocate to the interstitial space and become oxLDLs. Monocytes are attracted to the
insult. Diapediecisis occurs and monocytes are then differentiated into macrophages,
with scavenger receptors on the surface. The unregulated phagocytosis of oxLDL initiate
the phenotypic change in macrophages leading to the induction of the inflammatory
cascade. The oxLDL bind with high affinity to the macrophage scavenger receptor CD36
which stimulates the production of 2-AG. The ligation of 2-AG the CB2 receptor initiates
the anti-inflammatory response.
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5.2
5.2.1

Materials and Methods
Chemicals, cells, and reagents.
Trypan Blue solution (0.4% w/v), β-mercaptoethanol, fatty-acid free bovine

serum albumin (BSA), Avidin-horseradish peroxidase, and dimethyl sulfoxide (DMSO),
JZL184, Urea, TCEP, IAA, Trypsin, and all buffer components were purchased from
Sigma (St. Louis, MO). The activity-based serine hydrolase probe, fluorophosphonatebiotin (FP-biotin), was from Toronto Research Chemicals (North York, Ontario). HPLC
grade solvents, trypsin-EDTA, fetal bovine serum (FBS), penicillin, streptomycin,
HyperSep Retain PEP column, agarose beads, biospin columns, and were from ThermoFisher. Sep-PAK was purchased from Waters. SDS was purchased from Bio-Rad.
Human aortic smooth muscle cells, Vascular Basal Medium and Vascular Smooth
Muscle cell growth kit were purchased from the American Type Culture Collection
(ATCC) (Manassas, VA).
5.2.2

Cell culture conditions.
The human aortic smooth muscle cells were grown to 80% confluency during a

48 h incubation at 37°C, 5% CO2 in Vascular Cell Basal medium containing 5 ng/mL rh
FGF-basic, 10 mM rh Insulin (5 µg/mL EGF:5 ng/mL L-glutamine) 50 µg/mL Ascorbic
acid, and 5% FBS.
5.2.3

Preparation of cell lysates.
Adherent cells were incubated with 3 mL trypsin for 5 mins and reactions

quenched with 5 mL of culture medium. Subsequently, the cells were washed 2x and
collected into ice-cold 50 mM Tris-HCl (pH 7.4) buffer and lysed by sonication (three 15
114

s bursts on ice at 30% maximum power). Protein concentrations of cell lysates were
determined using the BCA reagent according to the manufacturer’s instructions (ThermoFisher).
5.2.4

Serine hydrolase profile.
Primary human smooth muscle cell proteomes (1 mg/mL, 30 µL reaction volume)

was treated with 8 µM fluorophosphonate (FP)-biotin for 1 h at room temperature
(vehicle for FP-biotin is DMSO, at a concentration of <1% v/v in the reaction).
Reactions with FP-biotin were terminated by addition of 5 µL 6x SDS-PAGE loading
buffer (reducing), heated at 90°C for 10 min, and then placed on ice. The labeled
proteins were separated by SDS-PAGE, and FP-biotin–labeled serine hydrolases were
detected by Avidin peroxidase blotting as previously described by us (Xie et al. 2010;
Wang et al. 2013). This gel-based ABPP approach permits rapid profiling of serine
hydrolase activities in the cells.
In addition to SDS-PAGE, cell proteomes were treated as described above using 1
mg/mL in a reaction volume of 1mL. Reactions with FP-biotin were terminated by
addition of 25 µL 20% w/v SDS, heated at 90°C for 5 min, and cooled on ice. The
labeled proteomes (400 µL) were filtered and centrifuged at 14,000g for 20 mins and
washed 3x with 450 µL of 50 mM Tris-HCl. The filter was reversed in a new
microcentrifuge tube, the top was washed with 100 µL of 50 mM Tris-HCl and the filter
was returned to the original position and washed 3x with 350 µL of 50 mM Tris-HCl by
centrifugation at 1,400g for 3 mins. The supernatant was stored overnight at 4°C. The
biotinylated proteins were captured with streptavidin beads. The beads were prepared in
1.5 mL EP tubes (200 µL of Agarose beads were centrifuged for 3 min at 1,400g, the
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supernate was discarded and beads washed 3x with 1 mL PBS). The samples were
allowed to incubate 4 h on rotator to bind to beads. Subsequently, the samples were
centrifuged for 3 min, the supernatant was discarded, and 1 mL of 0.2% SDS in PBS was
added to the beads and washed 3x with PBS followed by 3x with water for 10 min on
rotator. Then, 500 µL of 6 M urea in 50 mM Tris-HCl and 10mM fresh TCEP were
added to the beads and incubated for 15 min at 65°C without shaking. The samples were
cooled. Fresh 500 mM IAA was added to the samples and incubated 30 min at 37°C in
the dark without shaking; 950 µL of 50 mM Tris-HCl was added, centrifuged at 1400g
for 2 min and supernatant discarded; 200 µL of 2 M urea in 50 mM Tris-HCl, 2 µL
100mM CaCl2 was added to activate 1 mM trypsin, and 4 µL of Trypsin (20 µg
reconstituted into 40 µL of trypsin buffer was added and samples incubated overnight at
37°C on thermo-mixer at 500 rpm.
The bio-spin column was prepared according to manufacturer’s instructions, and
washed 3x with 400 µL of water. The peptides were collected by adding samples to
column and centrifuging at 1400g for 3 mins. The tube was washed with 50 µL of water
and transferred to the spin column and centrifuged 3x at 1400g for 3 mins. The eluent
was collected and added to 3 µL of 10% formic acid. The peptides were then desalted
and activated for evaluation with mass spectrometry. Briefly, Sep-Pak column was
activated with 5 mL the addition of 65% ACN plus 35% water containing 0.1% FA
(buffer B). The columns were equilibrated with 10 mL of 98% water plus 2% ACN
containing 0.1% FA (buffer A). The peptides were loaded to the column and the column
was again washed with buffer A. The collection tube was changed to a clean tube and the
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protein was eluted 2x with 500 µL of buffer B. The samples were dried under nitrogen
for proteomic analysis.
After Proteome Discovery searches, label-free quantization was accomplished by
normalizing the spectral counts for each identified serine hydrolase using the
commercially available software Scaffold 4.4.5, exactly as we recently published (Wang
et al. 2013) using ABPP-multidimensional protein identification technology (MudPIT)
for the detection of serine hydrolases for a higher resolution and sensitivity than gelbased ABPP.
5.2.5

Database Searching.
All LC-MS/MS samples were analyzed using Sequest (Thermo Fisher Scientific,

San Jose, CA, USA; version 1.3.0.339). Sequest was set up to search
Gallus_Salmonella_cont_Uniprot.fasta with the digestion trypsin enzyme. Sequest was
searched with a fragment ion mass tolerance of 0.80 Da and a parent ion tolerance of 10.0
PPM. Oxidation of methionine and carbamidomethyl of cysteine were specified in
Sequest as variable modifications.
5.2.6

Protein Identification.
Scaffold (version Scaffold_4.4.5, Proteome Software Inc., Portland, OR) was

used to validate MS/MS based peptide and protein identifications. Peptide identifications
were accepted if they could be established at greater than 65.0% probability to achieve an
FDR less than 0.1% by the Scaffold Local FDR algorithm. Protein identifications were
accepted if they could be established at greater than 98.0% probability and contained at
least 2 identified peptides. Protein probabilities were assigned by the Protein Prophet
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(Nesvizhskii et al. 2003). Proteins that contained similar peptides and could not be
differentiated based on MS/MS analysis alone were grouped to satisfy the principles of
parsimony. Proteins sharing significant peptide evidence were grouped into clusters.
5.2.7

Endocannabinoid metabolism of smooth muscle cells.
The cultured SMCs were treated with 10 µM exogenous 2-AG in serum-free

culture medium for up to 30 min in order to determine the extent of hydrolytic and
oxidative metabolism of this endocannabinoid by the cells. The culture medium was
harvested and reactions quenched by the addition of one volume of ACN containing 20
µL of deuterated arachidonic acid. The samples were placed on ice and the supernatant
was collected for LC-MS/MS metabolipidomic analysis of 2-AG. To determine if the
hydrolytic enzymes that play a role in the degradation of 2-AG, 0.25 mg/mL protein was
pre-incubated for 30 min with 1 µL carboxylesterase inhibitor paraoxon or MAGL
inhibitor JZL184, followed by a 30 min incubation with exogenous 2-AG. The reactions
were quenched by the addition of one volume of ACN and arachidonic acid levels
measured by UPLC analysis using well-defined methods published by us (Xie et al.
2010; Wang et al. 2013). In addition, the extent of cyclooxygenase-mediated oxygenation
of 2-AG was determined, as we have already done for human monocytes/macrophages
(Xie et al. 2010; Wang et al. 2013).
5.2.8

2-arachidonylglycerol hydrolysis.
To determine the rate of 2-AG hydrolysis, we seeded a 12 well plate with smooth

muscle cells to grow to 80% confluency followed by 30 min incubation with 10 μM 2arachidonylglycerol as substrate. The culture medium was extracted with 500 nM
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MHDG as internal standard using Sep-PAK and dried under nitrogen. The residues were
dissolved in 100 μL 1:1 (v/v) methanol:water for LC-MS/MS analysis. In subsequent
experiments, the cells were pre-treated with 10 µM VAS2870, an NADPH oxidase
inhibitor, followed by an additional 30 min incubation with 10μM 2-AG substrate and the
culture medium was extracted.
5.2.9

mRNA expression of Smooth muscle cells
Smooth muscle cells were grown to 80% confluency in a 12 well plate. The cells

were treated with pre-treated with 10 μM VAS2870 or DMSO for 30 min followed by 10
μM of AA for an additional 30 mins in an atmosphere of 37°C, 5% CO2. The culture
medium containing 500 nM MHDG was collected and extracted with HyperSep Retain
PEP as previously described (Wang et al. 2013). The samples were analyzed for 2-AG
biosynthesis by LC-MS/MS.
The SMCs RNA was isolated using RNeasy Plus Mini Kit according to the
manufacturer’s instructions. NanoDrop ND-1000 spectrophometer (Thermo Scientific,
Walham, MA) was used to quantify recovered RNA followed by cDNA synthesis using
iScript Select cDNA Synthesis Kit (BioRad) according to manufacturer’s instructions.
Real-time PCR of cDNA was performed on a Stratagene Mx3005P thermocycler with
Quantifast SYBR Green PCR master mix from Qiagen. Primers are detailed in Table 5.1.
The cycle program used for all target genes consisted of 5 min hot start at 95°C prior to
10 s at 95°C for 40 cycles, followed by 30 s at 60°C. The dissociation curve was
generated for PCR product quality immediately after analysis. Expression differences
were normalized using GAPDH and quantified using the ΔΔCT method. The results
generated were in fold differences of gene expression.
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Primer sequence used for quantitative real-time PCR

Table 5.1
Gene
(Homo
sapien)
CB1
CB2
CD36

Forward Sequence

Reverse Sequence

CAACAAGTCTCTCTCGTCCT
CACTGATCCCCAATGACTAC
AGGACTTTCCTGCAGAATAACA

GATGAAGTGGTAGGAAGGC
CCACTCCGTAGAGCATAGAT
ACAAGCTCTGGTTCTTATTCACA

NOX2

CGAAATGATGGTGACTGGCT

CCCAGCCAGTGAGGTAGATGT

P47

ATTCACAAGCTCCTGGACGG

ACACGTCTTGCCCTGACTTT

phox

DAGLB

Hs_DAGLB_1_SG QuantiTect Primer Assay – QT00074319

GAPDH

Hs_GAPDH_1_SG QuantiTect Primer Assay – QT00079247

5.3
5.3.1

Results
Serine hydrolase profile
The proteomic ABPP-MUDPIT analysis identified 24 catalytically active serine

hydrolases in human smooth muscle cells (Table 5.2 and Figure 5.2). Surprisingly, we
did not identify any carboxylesterase or other secondary enzymes we speculated to be
involved in hydrolysis of eCBs. Through use of the FP-biotin activity based protein
profiling (ABPP) probe in both gel-based (Figure 5.3) and mass spectrometry-based
formats (Figure 5.2), we were able to identify several serine hydrolase enzymes including
MAGL, the primary hydrolytic enzyme of 2-AG, and an ABHD11 isoform.
5.3.2

Hydrolysis of 2-AG.
The human smooth muscle cells were shown to metabolically hydrolyze 2-AG to

AA when treated with to exogenous 2-AG (Figure 5.4A). However, in the presence of
PO and JZL184, CES and MAGL inhibitors, respectively, a decreased rate of 2-AG
hydrolysis was evident, which was greater in the cells that were treated with the MAGL
inhibitor compared to those treated with the CES inhibitor (p=0.028) (Figure 5.4B).
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However, S-3030, which is a specific reversible CES1 inhibitor, had no effect on 2-AG
hydrolysis activity in SMCs (Figure 5.4B). To determine whether NADPH oxidase has a
role in the production of 2-AG, the SMCs were stimulated with arachidonic acid in the
presence of VAS-2870 to inhibit NADPH oxidase. Treatment of SMC with ionomycin, a
compound known to increase intracellular calcium and 2-AG biosynthesis, followed a
similar trend in the presence of VAS-2870 (Figure 5.5A). Furthermore, the data
demonstrated that, not only was 2-AG biosynthesis increased with the treatment of AA, it
was significantly augmented by the presence of VAS-2870 (Figure 5.5B).
5.3.3

mRNA expression
Our findings indicate that, SMCs have the machinery to produce oxyradical stress

as dictated by the expression of mRNA of the NADPH oxidase complex. Furthermore,
these data revealed that SMCs have the genes to potentially express the transcripts for the
eCB receptors (both CB1 and CB2), CD36, NOX2, p47phox, and DAGLβ mRNA (Figure
5.6). The presence of the transcripts for the enzyme, DAGLβ, suggest it is feasible to
biosynthesize 2-AG in SMCs
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Table 5.2

Serine hydrolase profile of human smooth muscle cells
NCBI Molecular
Gene ID Weight

Protease (SP)
or Metabolic
Hydrolase
(mSH)

Protein name

Gene

fatty acid synthase

FASN

2194

273 kDa

mSH

dipeptidyl-peptidase 9

DPP9

91039

102 kDa

mSH

prolyl endopeptidase

PREP

5550

81 kDa

mSH

fibroblast activation protein, alpha
patatin-like phospholipase domain
containing 6

FAP

2191

88 kDa

mSH

PNPLA6

10908

146 kDa

mSH

dipeptidyl-peptidase 4

DPP4

1803

88 kDa

mSH

tripeptidyl peptidase II

TPP2

7174

140 kDa

SP

neutral cholesterol ester hydrolase 1

AADACL1

57552

50 kDa

mSH

N-acylaminoacyl-peptide hydrolase

APEH

cathepsin A

CTSA

5476

54 kDa

mSH

dipeptidyl-peptidase 8

DPP8

54878

97 kDa

mSH

monoglyceride lipase

MAGL

11343

31 kDa

mSH

lysophospholipase II
prolylcarboxypeptidase (angiotensinase
C)

LYPLA2

11313

25 kDa

mSH

lysophospholipase-like 1
platelet-activating factor acetylhydrolase
1b, catalytic subunit 2
platelet-activating factor acetylhydrolase
2

LYPLAL1

PRCP

PAFAH1B2
PAFAH2

327

5547
127018
5049
5051

81 kDa

56 kDa
24 kDa
26 kDa
44 kDa

mSH

mSH
mSH
mSH
mSH

SIAE

54414

58 kDa

mSH

abhydrolase domain containing 11

ABHD11

83451

17 kDa

mSH

lysophospholipase I

LYPLA1

10434

23 kDa

mSH

phospholipase A2, group XV

PLA2G15

23659

47 kDa

mSH

prolyl endopeptidase-like

PREPL

9581

77 kDa

mSH

retinoblastoma binding protein 9

RBBP9

10741

21 kDa

mSH

sialic acid acetylesterase
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Figure 5.2

Identification and quantification of serine hydrolases in smooth muscle
cells.

Serine hydrolase activity profile as determined by FP-Biotin ABPP-MudPIT. Relative
spectral counts was used to determined quantification and identification of smooth
muscle cells serine hydrolase ABPP-MUDPIT. Importantly, monoacylglycerol lipase
(MAGL; highlighted in red), the 2-arachidonylglycerol hydrolytic enzyme, was
identified. Data represent means ± SD of triplicate analysis.
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Figure 5.3

Gel based activity based protein profiling of SMCs.

SMCs were grown to 80% confluency. The cells were lysed by sonication and treated
with a biotinylated probe. SDS-PAGE revealed five serine hydrolases within the samples
of which was monoacylglycerol lipase (MAGL).
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Figure 5.4

2-AG hydrolysis of SMCs.

2-AG can be hydrolyzed by monoacylglycerol (MAGL) to its metabolites arachidonic
acid and glycerol. (A) SMCs were treated with 10 µM of exogenous 2-AG for 30 min
had an enhanced production of arachidonic acid (p=0.0004). (B) These results were
abrogated in the presence of PO (p=0.05) and JZL184 (p=0.03) but not effected by S3030. Data represents mean ± SD n=3. * p<0.05, Student’s t-test when two groups are
compared, one-way ANOVA (Student-Newman-Keuls method) when more than two
groups are compared.

125

Figure 5.5

2-AG catabolism of SMCs.

(A) SMCs were treated with 1 µM of ionomycin for 30 min had an enhanced production
of 2-AG which was further heighted by the inhibition of NADPH oxidase. (B) Using a
physiological stimulant, arachidonic acid (10 µM, AA) followed a similar pattern of
increased 2-AG biosynthesis which was further enhanced by the inhibition of NADPH
oxidase with 10 µM VAS2870. Data represents mean ± SD n=3. * p<0.05, Student’s ttest when two groups are compared, one-way ANOVA (Student-Newman-Keuls
method) when more than two groups are compared.

Figure 5.6

mRNA expression of SMC

RT-PCR suggest SMCs have the ability to produce oxidative stress as indicated by the
relative gene expression both cannabinoid receptors (CB1 and CB2), scavenger receptor
CD36, DAGL, and NADPH oxidase subunits, NOX2 and p47phox. Data represents mean
± SD n=3.
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5.4

Discussion
Serine hydrolases are the most abundant and diverse classes of enzymes in

eukaryotic cells. They include lipases, thio-esterases, amidases, peptidases and proteases
(Bachovchin and Cravatt 2012). They represent approximately 1% total of the total
proteomes and play a vital role in the physiological processes pertaining to atherogenesis.
Serine hydrolases and proteases play roles in cardiovascular disease, such as (a) blood
coagulation pathways via activation of zymogens can lead to insoluble fibrin clot
formation (Davie and Ratnoff 1964; Macfarlane 1964; Bachovchin and Cravatt 2012), (b)
activation of platelets by fibrinogen being cleaved into fibrin via thrombin, the final
protease in the clotting cascade (Gustafsson et al. 2004), and (c) improve β cell function
and promote insulin secretion by dipeptidyl peptidase 4 (Meier et al. 2002; Rosenblum
and Kozarich 2003).
This is the first report to identify the serine hydrolases present in the human
smooth muscle cells. The vast majority of research has been geared toward the use of
pharmaceuticals that will inhibit the mechanism of action of these enzymes, but with
limited success. As we have demonstrated in previous reports, serine hydrolases CES1,
PPT1, MAGL, FAAH, ABHD6 and ABHD12 play a role in the degradation of
endocannabinoid ligands, which leads to the production of AA that is metabolized by
cyclooxygenases to prostaglandins. These data provide the ground work for
endocannabinoid research as a mechanism to modulate inflammation, as seen with
atherosclerosis by means of sustaining the presence of 2-AG. Of the hydrolases currently
known to degrade 2-AG into its metabolites arachidonic acid and glycerol, MAGL was
found to be present at a significant level in the SMCs, whereas CES1, PPT1, and FAAH
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were undetectable. The data presented here established that MAGL is the primary
hydrolytic enzyme in human SMCs. Because we previously demonstrated in
macrophage-like cells that 2-AG biosynthesis could be enhanced when NADPH oxidase
was activated, we examined whether a similar mechanisms was in play in SMCs. In the
SMCs, however, the response to NADPH oxidase was contrary to findings in the other
cell lines. These data indicate the ability of SMCs to produce the ligand 2-AG when
intracellular calcium levels rise. It is suggested that the SMCs undergo phenotypic
changes that produce markers similar to those of phagocytic cells when stimulated with
oxLDL. Products that mimic natural proteins with the ability to convert endogenous
substrates into inhibitors of inflammatory markers can be achieved via the serine
hydrolases of the SMC.
Small molecule drugs have been clinically approved for the use of targeting serine
hydrolases (Bachovchin and Cravatt 2012); however, of the six approved drugs only the
DPP4 is found in the SMC. Because modulating the eCB system has become a focus for
ameliorating atherosclerosis, the activation of eCB receptors and the enzymes that
produce and degrade their ligands to elicit therapeutic benefits of inhibitors with specific
targets. The availability of approved marketed drugs that inhibit serine hydrolases has a
broad affinity for hydrolases, thus the rate of inhibition could be higher in the face of
limited ability of the pharmaceutical industry to create a drug that specifically target a
serine hydrolase. Additionally, with the large number of reactive oxygen species
available to convolute experimental protocols, further studies are required to validate the
increase in 2-AG biosynthesis with the inhibition of the "professional ROS producer"
NADPH oxidase and the enzymes that degrade 2-AG once synthesized.
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This novel finding of serine hydrolases in SMC will pave the way for research
generating genetic or chemical therapies to enhancing the eCB system to decrease the
occurrence of atherosclerosis. Studies to include chemical or genetic deletion of these
enzymes can potentially reduce (a) the risk of coronary heart disease through PLA2
(Packard et al. 2000), (b) preeclampsia and body weight by modulating angiotensin
(Ang) II and Ang III with inhibition of PRCP (Mallela et al. 2009), and lipogenesis via
FASN (Menendez and Lupu 2007). The pursuit of selective inhibitors of SMC serine
hydrolases coupled with enhancing 2-AG biosynthesis can lead to the generation of
beneficial pharmaceuticals to combat atherogenesis.
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CHAPTER VI
CONCLUSION AND FUTURE DIRECTION
6.1

Conclusion
Despite a sea of research to understand its causes, cardiovascular disease (CVD)

still claims the lives of over 17 million people each year in the U.S. Of these deaths, four
of five CVD deaths are due to the consequences of either myocardial infarction or
strokes. Most individuals at risk for CVD do not display outward signs until the disease
has advanced. Moreover, CVD is a secondary complication of hypertension, obesity, and
diabetes. The cost of controlling the risk factors and the symptoms of CVD are well
above $400 billion dollars per year in the U.S., but surprisingly statin treatment is the
most common, least cost effective therapy (Franco et al. 2007). It is well known that
atherosclerosis is both genetically and environmentally provoked within an individual.
Although no one can change their genetics, it is possible to change behavioral patterns,
such as increased exercise, healthy diet, and possibly pharmaceutical therapy, to offset
the effects of hypertension, obesity, and hypercholesterolemia.
Inflammation is also known to have an important role in CVD. There are several
pathways that regulate pro- and anti-inflammatory cascades in cells. Previous research
indicated that modulating the endocannabinoid (eCB) system can decrease lesion
formation in the aorta. Furthermore, hydrolytic enzymes that degrade eCBs by small
molecules might have a role in regulating inflammation.
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This dissertation explored the role of the eCB system in monocytes/macrophages
that are subjected to oxidative stress. It was demonstrated that both endogenous and
exogenous oxyradicals could enhance the biosynthesis of 2-arachidonylglycerol (2-AG),
a lipid mediator associated with lowering inflammation. Specifically, examination of
how oxLDL-CD36 (scavenger receptor) binding induces oxidative stress and the
production of 2-AG was examined in Chapter 3. In chapter 4, the most significant
finding concerning oxyradical stress was that an NADPH oxidase stimulant (phorbol
ester) or arachidonic acid, extracellular xanthine oxidase, and oxLDL could stimulate
oxyradical stress, which resulted in enhanced 2-AG biosynthesis. We were able to
identify a role for NADPH oxidase in the increased eCB “tone” (i.e., increased
concentration of 2-AG) (Figure 6.1). This was supported by inhibiting the formation of
the NADPH oxidase complex and then measuring the levels of 2-AG production, which
were consequently reduced. These data support the idea that macrophages have
important roles in the metabolism of lipids that have roles in regulating inflammation.
There has been recent reports suggesting that upregulating the eCB system can cause
Gi/o to inhibit the function of Ras-proximate-1-GTPase activating protein (Rap1-GAP)
allowing Rap1-GTP to remain in its “on” state (Figure 6.2). Disallowing Rap1-GTP to
shut off leads to downstream signaling that disassemble the Nox complex, thereby
suppressing ROS generation (Han et al. 2009). Although current therapies for CVD
target well-established risk factors such as hypercholesterolemia and blood pressure, the
eCB system and the oxidoreductases that generate reactive oxygen species are emerging
targets for mitigating inflammation and oxyradical stress in the cardiovascular wall. The
research presented in this dissertation confirms previously published data that oxidized
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low-density lipoproteins can cause oxidative stress via the ligation of scavenger receptors
such as CD36, leading to oxidative and pro-inflammatory responses. However, the
connection between increased NADPH oxidase activity and endocannabinoid production
is a novel discovery and suggests that oxidative stress can result in the increased
biosynthesis of 2-AG.
While ROS appears to induce the biosynthesis of 2-AG, these eCB ligands work
locally and are short lived due to their rapid degradation by hydrolytic enzymes. Because
macrophages have a vital role in lipid metabolism, they are the most studied peripheral
cell types with regard to eCB hydrolytic enzymes. However, this dissertation presented
the first report of the nature of the eCB hydrolytic enzymes that are found in human
smooth muscle cells (SMCs) in chapter 5. In future studies, phagocytic cells and SMC
could be studied together in co-culture to determine the pathways for 2-AG hydrolysis by
serine hydrolases, because these cell types are found to neighbor one another in the vessel
wall. Additionally, SMCs catabolize 2-AG via monoacylglycerol lipase (MAGL)dependent hydrolysis and with their close proximity in the vessel wall, SMCs may assist
in the degradation of 2-AG released by neighboring macrophages. Several previous
reports have suggested that the factors that initiate inflammation in macrophages can also
alter the phenotype and function of SMC. Mechanistic pathways that alter the phenotype
of SMC resulting in the promotion of a lipid-laden cell phenotype is a viable area for
exploration. The data on SMC serine hydrolases will provide additional resources into
the investigation of specific inhibitors for serine hydrolases such as MAGL as a
therapeutic regimen (Figure 6.3), as opposed to the general hydrolase inhibition that is
seen with current drug therapy. To support the notion that CB2 is a protective response,
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Hoyer et al (2011) used ApoE-/-CB2-/- mice that are more prone to atherosclerosis than the
ApoE-/- alone to indicate knocking out CB2 increases the superoxide production and
increase macrophage infiltration into the vessel wall. The effects of heightened CB2
decreases monocyte migration to the site of vascular inflammation, chemokine receptors,
vascular cell adhesion molecule 1 and intracellular adhesion molecule 1 on endothelial
cells, and interferon gamma by lymphocytes. This research elucidates the links between
oxyradical stress, NADPH oxidase activity, and enhanced 2-AG biosynthesis (Figure
6.3). Because inflammation and oxidative stress are hallmarks of cardiovascular disease,
the data in this dissertation coupled with previous reports, provides evidence of
compensatory pathways to reduce oxidative stress in macrophages. In addition, it suggest
a mechanism by which oxyradical stress can be reduced via enhanced eCB tone.
6.2

Future Directions
Further investigation into the role of the eCB receptors is needed to distinguish

between the CB1 and CB2 receptors in oxidative stress. The conundrum of the eCB
receptors is that their downstream pathways can counteract each other during intracellular
redox state. Therefore, it is important to provide more evidence for the role of each
receptor in transducing signals derived from 2-AG, and how this signaling might
decrease inflammatory cascades during oxidative stress and shear stress in the vessel
wall.
The investigation of CB2 receptor signaling due to oxidative stress and the ability
to sustain the presence of the ligand for this receptor could inhibit the inflammation
associated with CVD. Although current pharmaceuticals that target serine hydrolases are
non-specific, more studies are needed to specifically target SMC serine hydrolases as a
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means of abrogating the differentiation of SMC into a lipid-laden phenotype. It is known
that inhibition angiotension (Ang) II signaling is associated with decreased CVD
symptoms, as seen with the prevalence of sartan prescriptions in the clinical setting.
With the SMC serine hydrolases now identified, coupled with the serine hydrolases that
have been identified in phagocytic cells, it will be beneficial to explore how stabilizing
the levels of 2-AG in these cells can be used as a treatment modality for reducing
atherosclerosis.
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Figure 6.1

Oxyradical stress can activate NADPH oxidase, which results in a
compensatory increase in 2-AG synthesis that might have beneficial
effects.

The activation of NADPH oxidase by oxLDL binding to scavenger receptors such as
CD36 can lead to the upregulation of DAGLβ, the second messenger to the biosynthesis
of 2-AG, thereby enhancing “endocannabinoid tone”. Additionally, 2-AG can be
hydrolyzed by MAGL, which is found in both macrophages and SMCs, to its metabolites
AA and glycerol.
Oxidized low density lipoproteins, oxLDL; reactive oxygen species, ROS, diacylglycerol
lipase beta, DAGLβ; 2-arachidonylglycerol, 2-AG; monoacylglycerol lipase, MAGL;
arachidonic acid, AA; monocyte chemoattractant protein-1, MCP-1.
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Figure 6.2

Upregulated endocannabinoid system reduce oxidative stress.

The enhanced level of endocannabinoid could be a negative feedback to reduce
oxyradical stress. The conical signaling pathway is via Gi/o, which acts to inhibit
adenalate cyclase; however, Gi/o, could also inhibit the function of Rap1-GAP to maintain
Rap-GTP in its “on” state leading to downstream signaling that can potentially
disassemble the NADPH oxidase complex, thereby suppressing ROS generation.
Cannabinoid receptor 2, CB2; adenalate cyclase, AC; cyclic adenosine monophosphate,
cAMP; Ras-proximate-1, RAP1; guanosine diphosphate/triphosphate, GDP/GTP;
GTPase activating protein, GAP; GTP exchange factor, GEF; reactive oxygen species,
ROS.
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Figure 6.3

Scheme suggesting the significance for therapy.

Oxidative stress can initiate pathways leading to the activation of the Nox complex
leading to enhanced ROS. Formation of ROS stimulate the downstream pathway leading
to cholesterol efflux to maintain homeostasis. Alternatively, ROS can leads to the
upregulation of DAGLβ, the second messenger in the biosynthesis of 2-AG which can
potentially lead to anti-inflammatory effects. The compilation of research indicated in
these chapters are summarized in purple.
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